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a  b  s  t  r  a  c  t
Targeted  therapies  and  the consequent  adoption  of  “personalized”  oncology  have  achieved  notable
successes  in  some  cancers;  however,  signiﬁcant  problems  remain  with  this  approach.  Many  targeted
therapies  are  highly  toxic, costs  are  extremely  high,  and  most  patients  experience  relapse  after  a  few
disease-free  months.  Relapses  arise  from  genetic  heterogeneity  in  tumors,  which  harbor  therapy-resistant
immortalized  cells  that  have  adopted  alternate  and  compensatory  pathways  (i.e., pathways  that  are not
reliant  upon  the  same  mechanisms  as  those  which  have  been  targeted).  To  address  these  limitations,  an
international  task  force  of  180 scientists  was  assembled  to explore  the  concept  of  a low-toxicity  “broad-
spectrum”  therapeutic  approach  that  could  simultaneously  target  many  key  pathways  and  mechanisms.
Using  cancer  hallmark  phenotypes  and  the  tumor  microenvironment  to account  for  the  various  aspects
of  relevant  cancer  biology,  interdisciplinary  teams  reviewed  each  hallmark  area  and  nominated  a wide
range  of  high-priority  targets  (74 in  total)  that  could  be modiﬁed  to improve  patient  outcomes.  For  these
targets,  corresponding  low-toxicity  therapeutic  approaches  were  then  suggested,  many  of  which  were
phytochemicals.  Proposed  actions  on each  target  and  all of  the  approaches  were  further  reviewed  for
known  effects  on  other  hallmark  areas  and  the tumor  microenvironment.  Potential  contrary  or  procar-
cinogenic  effects  were  found  for 3.9%  of  the  relationships  between  targets  and hallmarks,  and  mixed
evidence  of complementary  and  contrary  relationships  was  found  for 7.1%.  Approximately  67% of  the
relationships  revealed  potentially  complementary  effects,  and  the  remainder  had  no  known  relationship.
Among  the  approaches,  1.1%  had  contrary,  2.8%  had  mixed  and 62.1%  had  complementary  relationships.
These  results  suggest  that  a  broad-spectrum  approach  should  be feasible  from  a safety  standpoint.  This
novel  approach  has  potential  to be relatively  inexpensive,  it should  help  us address  stages  and  types  of
cancer  that  lack  conventional  treatment,  and  it may  reduce  relapse  risks.  A proposed  agenda  for future
research  is  offered.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
Cancer is a source of signiﬁcant and growing mortality world-
ide, with an increase to 19.3 million new cancer cases per year
rojected for 2025. More than half of cancer cases and mortality
ccur in low- and middle-income countries, and these proportions
re expected to increase by 2025 [1]. Current treatments for cancer
nclude surgery, radiotherapy and systemic treatments compris-
ng cytotoxic chemotherapy, hormonal therapy, immunotherapy,
nd targeted therapies [2]. Cancer continues to stymie clinical
reatment efforts, however, and the search for effective therapies
ontinues.
This capstone paper describes the methods and results of a sub-
tantial effort by a large international group of biochemical and
edical researchers, operating under the name of “The Halifax
roject,” sponsored by a non-proﬁt organization, Getting To Know
ancer. It summarizes and draws together material from a series of
eviews on the hallmarks of cancer, presented in this special issue
f Seminars in Cancer Biology, to present a conceptual framework
or a new approach to cancer prevention and therapeutics. This
pproach involves the targeting of many speciﬁc high-priority anti-
ancer mechanisms and pathways within a more comprehensive
odel of treatment and care. We  refer to this as a “broad-spectrum”approach (i.e., an approach aimed at a broad spectrum of impor-
tant mechanisms and pathways) [3]. The broad-spectrum approach
involves combinations of multiple low-toxicity agents that can col-
lectively impact many pathways that are known to be important
for the genesis and spread of cancer. By making extensive use of
chemicals from plants and foods that have already been studied or
utilized for cancer prevention and treatment, this approach offers a
compelling rationale for addressing the underlying biology of can-
cer while being efﬁcacious, non-toxic and cost-effective. We  come
together in the belief that a broad-spectrum approach of this type,
in the context of a therapeutic environment including conventional
treatment and attentive to optimal health, would provide genuine
beneﬁt in clinical outcomes for cancer patients. In this paper we
describe the rationale for broad-spectrum therapeutics, detail the
methods of the Halifax Project, summarize potential targets and
agents related to eleven hallmark features of cancer, propose a
research model for the development of broad-spectrum therapies,
and call for action to advance this research model.
1.1. Rationale for broad-spectrum approachPrimary motivations for the development of a broad-spectrum
approach stem from the distinct limitations that are evident in
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pig. 1. Diagrammatic representation of removal of susceptible cells by a targeted
esistant cells to proliferate, resulting in relapse.
any current targeted therapies and the personalized medicine
aradigm. Molecular target therapies represent a signiﬁcant
dvance in the treatment of cancer. They include drugs such as
matinib, an inhibitor of the tyrosine kinase enzyme BCR-ABL,
hich has made chronic myelogenous leukemia a more manage-
ble disease, and inhibitors of vascular endothelial growth factor
eceptor (VEGFR), such as sunitinib, sorafenib and bevacizumab,
sed in renal and colon cancers [2]. Other important treatments
ased on tumor-speciﬁc targets are now in use, including exam-
les such as epidermal growth factor receptor (EGFR) inhibitors
geﬁtinib, erlotinib) used in lung cancer, and the Her2 inhibitor
rastuzumab used in breast cancer. Another approach is the syn-
hetic lethal model [4] exempliﬁed by research on poly ADP ribose
olymerase (PARP) inhibition, in which mutational loss of one
r more redundant components of a cell survival pathway in
umorigenic cells confers selective sensitivity to drugs that target
emaining pathway components.
These drugs target cells bearing one, or at most a few mutated
ene products or other abnormalities not found on normal cells.
n the therapeutic context, the action of the targeted agents can
fﬁciently address malignant cells, without some of the effects on
ormal cells notorious in cytotoxic chemotherapy. This enables
herapeutic responses and remissions. Over time, however, the
enetic heterogeneity of tumors increases, engendering resistance
o treatment. Resistant cells drive the emergence of increasingly
ggressive disease, through clonal expansion and clonal evolu-
ion (Fig. 1). Epigenetic modiﬁcations, heritable cellular changes
ot caused by alterations to DNA sequences, but by alterations
uch as methylation of DNA or modiﬁcation of the histone protein
ssociated with DNA, may  also affect patterns of gene expres-
ion and drive cancers [5]. Relapses often occur after only a few
onths, and tumors reappear, sometimes in exactly the same areas
n which they originated [6]. Moreover, targeted agents are not
ithout serious side effects, such as treatment-related mortality
ith bevacizumab and cardiopulmonary arrest with cetuximab.
eta-analysis of trials of recently approved cancer drugs includ-
ng targeted therapies versus older drugs showed increased rates
f grades 3 and 4 toxicity (OR = 1.52), treatment discontinuation
OR = 1.33) and toxic deaths (OR = 1.40) [7]. This worsening of
dverse effects has gone in large part unacknowledged.
The efﬁcacy shown to date with targeted therapies, aside
rom now-established treatments such as bevacizumab and
rastuzumab, is nevertheless still limited. Sunitinib, for instance,
xtends overall survival by 4.6 months in renal cancer compared
ith the previous treatment of interferon- [8]. While statistically
igniﬁcant, this degree of improvement is small comfort to afﬂicted
atients, and challenges the extraordinary monetary investment
n drug development as well as costs to the medical system that
argeted therapies represent. The MOSCATO 01 trial of molecular
riage was able to treat 25 of 111 patients with a variety of advanced
ancers using therapies targeted to genomic alterations assessed
rom tumor biopsies [9]. Of these, 5 patients (20%) experienced
artial response and 56% had stable disease. Based on the entirer therapy resulting in disease remission, which leaves genetically heterogeneous
population of 111 patients, this is a partial response of less than 5%,
suggesting limited efﬁcacy to date, an outcome also seen in some
other studies [10]. On a more hopeful note however, a combina-
tion of pertuzumab with trastuzumab and the chemotherapy agent
docetaxel was recently found to extend overall survival among the
subset of breast cancer patients whose tumors express Her-2 by
15.7 months [11].
Interestingly, harnessing the body’s immune response against
the tumor can also result in impressive durable clinical responses,
perhaps because the immune system is a paragon of adaptabil-
ity and can deal with changes in the mutational landscape of
cancer to prevent escape from the therapeutic effect. Immunomod-
ulatory antibodies recently licensed in the United States include
ipilimumab as well as nivolumab and pembrolizumab, neutraliz-
ing two  different inhibitory pathways that block antitumor T cell
responses. These agents have achieved some successes in treating
late stage cancers refractory to essentially any other treatments
[12]. But even with these agents, response rates are still low and
predicting who will respond is an unsolved challenge [13,14].
Many of these therapies are somewhat narrowly described as
“personalized” because patients’ tumors must be tested for spe-
ciﬁc mutations to stratify patients to the correct therapy. Viewed
in the larger context of individual biological variation, of course,
speciﬁc mutations drive only the smallest degree of personali-
zation. Truly personalized treatment approaches can be seen to
include a much more comprehensive assessment of genetic and
even lifestyle factors, such as nutritional, biobehavioral (stress
management) strategies, and exercise habits, along with other
host variables such as inﬂammation and immune status. Such an
approach to personalizing treatment can be found in the systematic
practice of integrative medicine, which played a signiﬁcant role in
the development of this model of broad-spectrum cancer therapy.
Some deﬁnitions of integrative medicine stress simply the inclusion
of complementary and alternative therapies alongside orthodox
treatment [15]. A more relevant deﬁnition emphasizes a patient-
centered, multi-intervention treatment paradigm that addresses
the full range of physical, mental, emotional and environmental
inﬂuences, utilizing an array of disciplines including diet, mind-
body and physical activity therapies in addition to conventional
therapies and dietary supplements to support optimal health [16],
based on laboratory testing that enables comprehensive persona-
lization.
The stratiﬁcation of patients for these targeted and person-
alized therapies poses practical challenges. As indicated earlier,
over 50% of the increase in cancer incidence by 2025 is projected
to occur in the developing world [1]. As industrialization devel-
ops in lower-income countries, occupational cancers are expected
to increase, potentially aggravating this situation [17]. Cancer
treatment in many of these countries is already becoming a social-
economic challenge due to the expense and medical infrastructure
required [18], and the new generation of treatments may  further
strain local resources. Currently, the platforms used for testing
to personalize regimens include whole exome or whole genome
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equencing, whole transcriptome sequencing, and comparative
enomic hybridization with still others in development. It is likely
hat such tests, and related expense, will proliferate in the future.
anaging treatment toxicity is also a taxing and complex problem,
s these toxicities necessitate additional medical interventions.
The expense of the new targeted therapies is also concerning.
leven of twelve drugs approved by the US Food and Drug Admin-
stration (US FDA) in 2012 were priced above $100,000 US per year
er patient – perhaps not surprisingly in view of the accelerating
osts of drug development [19]. Clinicians have drawn attention
o these high costs: in 2013 more than 100 experts in chronic
yeloid leukemia coauthored a paper calling for lower prices
nd broader access to these drugs [20]. The excessive costs have
esulted in drugs not being approved for use by national or regional
overnments where cost-beneﬁt analyses ﬁgure in approval pro-
esses [21]. While costs are expected to decrease after expiration
f patents on the drugs, the costs for treatment in low- or middle-
ncome countries may  continue to be problematic. The potential
or unsupportable ﬁnancial stress on health systems challenges the
esearch community to explore other treatment models that can
e more sustainable in the face of the worldwide increase in cancer
ncidence.
The broad-spectrum approach that we describe here is primarily
ntended to address the two major issues of therapeutic resis-
ance and cost. It is based on many of the insights of genomic
equencing in cancers. We  now know that cancers harbor signif-
cant genetic heterogeneity, even within a single patient [6]. Based
n this heterogeneity, cancers routinely evolve resistance to treat-
ent through switching from one growth pathway to another [22].
he proposed strategy employs the basic principles of rational drug
esign, but aims to stem cancer growth by precisely targeting many
rowth pathways simultaneously. Some effort is now being made
n combining targeted agents so that more than one pathway can
e affected, but lack of therapeutic success, signiﬁcant toxicity and
osts make this a challenge [23–26].
We see the broad-spectrum approach as one that is comple-
entary to existing therapies, preferably within the context of a
enuinely integrative clinical system. Clinical situations in which
uch an approach might prove useful include (a) as a follow-up
aintenance plan to conventional adjuvant treatment; (b) in sit-
ations of rare cancers and disease stages for which no accepted
reatments exist; (c) for patients who do not tolerate conven-
ional chemotherapy, hormonal therapy or targeted therapies; (d)
or patients who experience relapse or progression after targeted
reatment; (e) in hospice or palliative care patients where low- or
on-invasive strategies are a legitimate and humane option; and (f)
n situations in which high-cost agents cannot be obtained. Because
f continuous heterogeneity among cancer cells, and their propen-
ity for genomic instability, even a broad-spectrum approach is
nlikely to cause complete remission. However, the design of this
pproach posed a substantial theoretical challenge, for which we
hose to use the hallmarks of cancer as a broad organizing frame-
ork.
.2. Hallmarks of cancer as a framework for developing
road-spectrum therapeutics
Hanahan and Weinberg ﬁrst published their concept of the
allmarks of cancer in 2000 [27]. The hallmarks “constitute
n organizing principle that provides a logical framework for
nderstanding the remarkable diversity of neoplastic diseases.”
his framework encompasses the biological capabilities that
ells acquire during the development of cancers that allow
hem to become malignancies as we know them. Six hallmarks
ere proposed in the 2000 publication: sustained proliferative
ignaling, evading growth suppressors, activating invasion andBiology 35 (2015) S276–S304 S281
metastasis, enabling replicative immortality, inducing angiogen-
esis and resisting cell death. The concept of the hallmarks became
widely recognized and inﬂuential. In 2011, Hanahan and Weinberg
expanded on the initial hallmarks to include other areas of cancer
biology that they felt were equally important [28]. They pointed out
two enabling characteristics critical to the ability of cells to acquire
the six hallmarks, and two  new hallmark capabilities. They also sin-
gled out the crucial nature of the complex tumor microenvironment
in the appearance of the cancer phenotype. The enabling character-
istics are genomic instability and tumor-promoting inﬂammation;
the new hallmarks are deregulating cellular energetics and avoid-
ing immune destruction.
The hallmarks framework helps to deﬁne domains in which high
priority targets can be identiﬁed for therapeutic targeting. Hanahan
and Weinberg point out that agents are in development that target
each of the hallmarks. They also note, however, that in response to
targeted therapy, cancers may  reduce their reliance on a particular
hallmark capability, such as angiogenesis, and instead heighten the
activity of another capability, such as invasion and metastasis [29].
This reaction has been clinically veriﬁed in the case of glioblastoma
[30].
Another model, which was proposed by Vogelstein et al. in
2013 [6], also attempts to describe the mechanisms and path-
ways that are relevant to many cancers. In this model, “driver”
genes that drive cancer growth are distinguished from “passenger”
mutations found in cancer cells that impart no growth advan-
tage. Twelve major signaling pathways that drive cancer growth
have been elucidated, including signal transducers and activators
of transcription (STAT), Notch, DNA damage control and 9 others.
These pathways are classiﬁed into three cellular processes underly-
ing tumor growth: cell survival, cell fate and genome maintenance.
Individual patients with the same cancer can have mutations on dif-
ferent pathways, leading to inter-patient heterogeneity. Yet within
each patient there is also substantial heterogeneity, both within
each patient’s primary tumor, and among and within metastases,
with signiﬁcance for treatment strategies. For instance, the small-
est metastases visible through medical imaging may  already have
thousands of cells that harbor mutations rendering them resistant
to current drugs [31].
Cancer mutations, moreover, are not simply a series of isolated
targets. Beneath the surface of the cancer genome is a notably
complex cellular signaling network, ﬁlled with redundancies. The
elucidation of rational therapeutic combinations requires dynamic
mechanistic models that reach beyond simple targeting [32]. What
propels growth, dissemination and thus ineffective treatment and
drug resistance actually appears not to be pathways acting in iso-
lation but interconnected, multidirectional and dynamic networks
[33]. Even sorafenib, which inhibits multiple kinases, is susceptible
to the rapid development of resistance deriving from crosstalk in
pathways such as phosphatidylinositide 3-kinase/protein kinase B
(PI3K/Akt) and Janus kinase (JAK)-STAT, hypoxia-induced signaling
or the epithelial-to-mesenchymal transition (EMT) [34]. Conven-
tional drug discovery programs are now contemplating systems
biology approaches aimed at furthering the network approach
to pharmacology. The interdependence of cytokines, chemokines,
growth factors, transcription factors, and their resulting proteomes,
together with their relevance to cancer prevention and treatment
[35], makes systems biology approaches most attractive [36]. This
realization makes the signiﬁcance of a broad-spectrum approach
to cancer of even greater importance.
Clinicians as well as researchers recognize the importance of
heterogeneity in cancer. A least one clinical center recognizes
the signiﬁcance of this heterogeneity, and intervenes with broad-
spectrum approaches to respond to it. In a 2009 book, Life Over
Cancer, based on a clinic in operation since 1980, Block lays out
a model of nutraceutical-based targeting of nine “pathways of
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rogression” and six metabolic factors impacting the challenges
aced by all cancer patients [3]. The nine growth pathways are
roliferation, apoptosis, treatment resistance, immune evasion,
ngiogenesis, metastasis, cell-to-cell communication, differentia-
ion and immortality. Multiple targeting of these pathways with
atural products is used to simultaneously address multiple inter-
onnected growth pathways. Comprehensive molecular proﬁling
aps patients’ growth pathways and provides for relevant nat-
ral product intervention. The six metabolic “terrain factors” are
xidation, inﬂammation, glycemia, blood coagulation, immunity
nd stress chemistry. Terrain-focused interventions are tailored
o patients’ laboratory test results, which are monitored regularly
o guide therapeutic modiﬁcation. Interventions include elimina-
ion of maladaptive lifestyle patterns, adjusting exercise habits,
mproving diet, implementing biobehavioral strategies to dimin-
sh adverse consequences of unabated stress/distress, and using
atural products and medications that affect speciﬁc targets such
s C-reactive protein (CRP) [37], interleukin-6 (IL-6), nuclear fac-
or -beta (NF-B) [38], prostaglandin E2 and leukotriene B4 [39]
or inﬂammation. Clinical observations and literature review sug-
est potential efﬁcacy for this system in breast cancer (including a
ear-doubling of survival time of breast cancer patients in integra-
ive care) and potentially other cancers [40,41]. Essentially, Block’s
linical model systematically addresses multiple targets and path-
ays through a speciﬁc and selective broad-spectrum approach to
reatment. While this system was developed in clinical practice,
uite independently from the discussion of hallmarks and enabling
haracteristics by Hanahan and Weinberg, the conceptual overlap
s obvious. That these concepts have already been used in clinical
reatment provides powerful support for the viability of a carefully
esigned broad-spectrum approach.
The model we propose to use to develop a sound framework
or a broad-spectrum approach recognizes these broad areas of
onceptual overlap and agreement, and can be considered to best
lign with the hallmarks of cancer framework [27]. Our framework
ncompasses the molecular and metabolic diversity of malignancy
ecognized in Hanahan and Weinberg’s hallmarks, Vogelstein’s 12
rowth pathways, Block’s pathways of progression and terrain fac-
ors, and other emerging research. For the purposes of this project,
e treat the 6 hallmarks, 2 enabling characteristics, 2 emerging
allmarks, and the tumor microenvironment equally as hallmarks
f malignancy. From a design standpoint, each of these individual
reas encompasses an important aspect of cancer’s biology, so each
as seen as important to consider for a therapeutic approach aimed
t a wide range of high priority targets.
In mid-2012, the framework for this project and approach were
hared with Douglas Hanahan. He later independently provided
upport for this type of approach in a paper, “Rethinking the war
n cancer” [42]. Using a military metaphor, he suggests a three-
imensional cancer “battlespace” plan that attacks cancer in a
ull-scale war rather than individually targeted skirmishes. The ﬁrst
imension is disruption of cancer’s many capabilities, speciﬁcally
hose ﬁguring in the hallmarks. Rather than just removing one capa-
ility, as targeted therapies do, he explains that an ideal approach
hould target all the hallmark capabilities. The second dimension is
efense against cancer’s armed forces, implying speciﬁc targeting
f the accessory cell types in the tumor microenvironment, such
s tumor-promoting inﬂammatory cells. The third dimension rep-
esents the multiple battleﬁelds of cancer: primary tumor, tumor
icroenvironment, lymph and blood vessels through which tumors
isseminate, draining lymph nodes and distant organs. This dimen-
ion suggests still more targets.A rapidly developing sub-discipline in oncology is the appli-
ation of genetic and immune analysis of tumor tissue and the
oncomitant use of personalized therapies and prescriptions. These
nalyses allow better stratiﬁcation of patients to treatments andBiology 35 (2015) S276–S304
clinical decision-making [43]. In the case of breast cancer alone,
tests range from Her-2 testing, the basis of trastuzumab treatment
to sophisticated suites of tests that analyze dozens of genes. These
complex analyses assist in treatment decisions based on correla-
tions with clinical outcomes by predicting treatment response, risk
of recurrence and outcome. They suggest the size of the network of
genes that affect just one cancer, and emphasize the signiﬁcance of
a broad-spectrum attack. Clinical utility of these tests is still under
review [44].
Despite impressive progress in genomic and gene expression
proﬁling, however, it is often impossible to fully characterize the
range of immortalized cell variants within any given cancer. The
perspectives offered by Hanahan, Vogelstein and Block, as well as by
the recognition of the network aspects of signaling pathways, how-
ever, suggest a larger number of targets may  need to be reached.
So the 138 driver genes, together with the 12 signaling pathways
that comprise them, in addition to the molecular contributors to the
hallmarks, and Block’s nine pathways of progression and six terrain
factors, help us delineate some of the most signiﬁcant targets that
should be taken into account in development of a broad-spectrum
approach.
2. Methods
The effort to develop the concept of broad-spectrum targeting
of cancer through a complex combination of agents, emphasiz-
ing naturally occurring chemicals, was developed by a non-proﬁt
organization, Getting To Know Cancer, and implemented within
an initiative called “The Halifax Project.” The aim of the project
was to produce a series of reviews of the cancer hallmarks that
could collectively assess and prioritize the many target choices
that exist, and also identify non-toxic chemicals (primarily from
plants or foods) that could safely be combined to produce an opti-
mized broad-spectrum approach that has both prophylactic and
therapeutic potential. To that end, it was envisioned that eleven
teams of researchers would produce reviews on the ten cancer
hallmarks plus the tumor microenvironment, which was  treated
as a hallmark for the purposes of this project. Each review was
to describe the hallmark, its systemic and cellular dysfunctions,
and its relationships to other hallmarks. A priority list of relevant
therapeutic targets and corresponding approaches suited to those
targets was requested, along with a discussion of research needed
in the context of goals of the project. Natural compounds were
emphasized because of the growing body of literature that sup-
ports the low toxicity and interesting potential that many of these
substances have demonstrated (i.e., as targeted therapeutics or in
cancer prevention), while recognizing the variable effectiveness of
these compounds in human trials as well as the undocumented
safety or frank toxicity concerns with many natural products [45].
In recognition of the network of signaling pathways involved not
only in drug resistance but the interconnection and maintenance of
all the hallmarks, the project implemented a cross-validation step
in the evaluation of targets and approaches. Because of the diversity
of the targets involved in the 11 hallmark areas, it is not unreason-
able to suspect that inhibiting or stimulating a target relevant to one
hallmark may have an adverse growth effect or clinically adverse
effect on a target in another hallmark. For instance, reducing DNA
damage is a potential target for counteracting genomic instabil-
ity. Activation of the immune system can counter DNA damage by
eliminating damaged cells. However, activation of the immune sys-
tem, while reducing overall levels of DNA damage, can contribute
to chronic inﬂammation [46].
Similar considerations apply to therapeutic approaches. For
instance, triptolide, a component of the Chinese herb Tripterygium
wilfordii, is known to cause apoptosis in cancer cells [47]. Extracts
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f the herb have been used in clinical trials for a variety of inﬂam-
atory and immune-linked conditions, and have demonstrated
oth antiinﬂammatory and immune suppressant activity, raising
oncern for its effect on immune evasion [48,49].
To address this issue, a specially designated cross-validation
eam was created within the project to evaluate all selected
argets and approaches, i.e., to determine whether the inhibi-
ion or activation of targets, and the application of approaches,
ould have negative effects on other hallmarks. Each potential
arget-hallmark or approach-hallmark interaction was  assessed
o determine whether the pair had a complementary interaction
i.e., the interaction of the target or approach with the hallmark
acilitated anticancer activity), a contrary interaction (i.e., the inter-
ction of the target or approach with the hallmark had a potential
dverse tumor-stimulating or tumor-progression effect), a con-
roversial interaction (i.e., mixed indications of anticancer and
umor-stimulating effects), or no known relationship. A sample
ross-validation table for dysregulated metabolism approaches can
e accessed as Supplemental Table S1.
It is important to note that the cross-validation team was not
iven any restrictions for literature selection for this effort, and
ontributing authors were not restricted to cancer-related research.
his approach was taken because it was realized at the outset that
his breadth and speciﬁcity of knowledge does not yet exist in the
iterature. As a result, the types and sources of data gathered in this
ffort varied considerably, although original studies were consis-
ently favored over review articles. Moreover, many studies that
ere cited in this effort considered only a compound’s ability to
nstigate or promote an action that mimics a hallmark phenotype
n a manner directionally consistent with changes that have been
ssociated with cancer. So while we refer to these as anticancer
r tumor-stimulating, the speciﬁcity of these activities and their
mplications for cancer treatment cannot and should not be imme-
iately inferred from this database. In other words, the results from
his aspect of the project were only compiled to serve as a starting
oint for future research, rather than a conclusive guide to therapy.
Targets or approaches that have a substantial number of
contrary” assessments are less attractive for inclusion in the
road-spectrum approach. On the other hand, the use of targets and
pproaches that appear to have the potential for multiple comple-
entary interactions is consistent with principles of rational drug
esign, and akin to efforts to design “dirty” drugs (a pharmacolog-
cal term for drugs with multiple targets – as opposed to single
argets – aimed at multidimensional conditions) [50]. Further eval-
ation of such “dirty” targets and approaches could be undertaken
hrough more speciﬁc application of network pharmacology, for
hich new tools are currently becoming available [51]. The tabu-
ated results, which appear in the individual reviews, are discussed
n a later section of this paper.
The review teams needed for the Halifax Project were formed by
rst circulating an email to a large number of cancer researchers,
eeking expressions of their interest in participation. The email was
irculated in July 2012 by Getting To Know Cancer, and scientists
ere encouraged to submit their details on a dedicated webpage
hat offered additional project detail. From the pool of 703 can-
er scientists who responded to the email, 11 team leaders were
elected to each lead a group in producing a review of each hall-
ark, and an additional leader selected for the cross-validation
eam. Those leaders were then asked to form their own  teams (by
rawing from the pool of researchers who expressed interest in the
roject, and from their own circles of collaborators). Ultimately,
2 teams were formed. Team members were each encouraged to
ngage a junior researcher as well. This led to fairly large teams but
t allowed us to distribute the effort considerably. Team leaders all
eceived project participation guidelines; extensive and ongoing
ommunication from the project leader, Leroy Lowe; copies of theBiology 35 (2015) S276–S304 S283
relevant papers of Hanahan and Weinberg; and copies of Life Over
Cancer by Block [3] as an example of practical clinical implementa-
tion of the broad-spectrum approach. In addition to the 11 teams,
two guest editors, Anupam Bishayee and Keith Block, were selected
for this special issue of Seminars in Cancer Biology in which the team
reviews are published.
The team leaders and other team members who  were able to
attend the project workshop met  in Halifax, Nova Scotia in August
2013 to discuss the project. Drafts of hallmark team papers were
submitted in advance, and summary presentations made at the
meeting. Other subject matter presentations included presenta-
tions on research funding in the natural products area (Jeffrey D.
White, Ofﬁce of Cancer Complementary and Alternative Medicine,
National Cancer Institute) and the concept of driver and pas-
senger genes (Bert Vogelstein, Johns Hopkins). Presentations on
integrative cancer therapeutics made at the meeting are summa-
rized below (Keith Block, Penny Block, Block Center for Integrative
Cancer Treatment). Group discussions were held to facilitate com-
munication among teams and project staff, and to assist teams in
exploring the requirements and rationale for selection of targets
and approaches.
Each hallmark team contained the following specialists: a lead
author with demonstrated expertise in the hallmark area; domain
experts who produced the descriptive review; anticancer phy-
tochemical specialists; oncologists; and support researchers. The
cross-validation team conducted background literature searches on
the submitted targets and compounds from each review team, veri-
fying their activity in relation to the other hallmarks. Results of the
cross-validation effort were tabulated and reviewed by the indi-
vidual teams. Ambiguous results and areas of disagreement were
reconciled, and the tables were ultimately incorporated into each
hallmark review.
2.1. Selection of targets and approaches
It was  assumed from the outset that, in a translational project
aimed at the development of a broad-spectrum approach, there
would be a practical upper limit to the number of potential tar-
gets in any given cancer that could be targeted. So each hallmark
team was  asked to select and prioritize up to 10 relevant targets for
their hallmark area, bearing in mind that each target would serve
as a starting point for the identiﬁcation of a suitable low-toxicity
approach that might be used to reach that target. In theory, it was
understood that this could lead to as many as 110 targets for the
entire project, and since the teams were also asked to select one
therapeutic approach for each target, a maximum of 110 potential
therapeutic approaches might be selected.
An “approach” was deﬁned in this project as (1) a technique that
will cause the body to respond in a manner that will act on the target
(e.g., fasting, exercise, etc.), or (2) a procedure involving an entity
that can act on the target (e.g., phytochemical, dietary modiﬁcation,
synthetic drug, vaccination with peptides, locally administered
oncolytic virus, etc.). Teams were then asked to identify “favored”
approaches with patient safety as a top priority (i.e., least likely to
cause harm or side effects even in combination with many other
approaches). In addition to safety, other practical considerations
for choosing favored approaches were suggested as follows:
• Efﬁcacy – greatest potential to achieve the desired action on the
intended target across the widest possible range of cancer types.
• Cost – less expensive is better, and by no means cost prohibitive.
• Intellectual property – free of intellectual property constraints if
at all possible. Approaches that do not have patents, that cannot
be patented, and/or those that have patents that are expired are
to be given priority over those that have existing patents.
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.1.1. Selection of targets
Extensive discussion took place about the principles of target
election. Certainly targets that are unique to cancer cells and tumor
icroenvironments, and that are not known to cause side effects
hen inhibited pharmacologically, would be a primary consider-
tion. Targets induced by viruses or known carcinogens that are
f importance in therapy would also be examined. Consideration
f the nature of mutations in the cancer genome and the role of
pigenetic modiﬁcation were also discussed.
It is understood that great effort has been made to sequence the
ancer genome to identify the most common mutations seen in dif-
erent cancers. It is also known that different driver mutations may
ive rise to variant tumor cells, and the number of driver mutations
equired is limited, with just 2–8 per patient, which could poten-
ially be assessed through whole genome sequencing of individual
ancer patients. However, questions arise about treatment, since
ost of the currently available drugs are not potent enough to tar-
et all susceptible cells. Moreover, the toxicity of existing drugs, if
dministered in combination protocols, is severely limiting, even
t the reduced dosages that may  be possible when using multi-
le agents. A strong rationale supports focusing on low toxicity
hemistry (e.g., such as that which has been demonstrated by many
nticancer and chemopreventive phytochemicals as the founda-
ion for a broad-spectrum approach. A number of phytochemicals
nhance absorption of other natural products through such mech-
nisms as cytochrome P450 modiﬁcation [52], which could also
nhance the possibilities for low-toxicity treatment, i.e., by reduc-
ng dosages needed for effective treatment.
Many driver genes are actually tumor suppressor genes, and
n these cases, it is the loss of the tumor suppressor gene that
llows development of cancer. Drugs cannot target these miss-
ng genes. Rather they must target unopposed pathways, such
s pathways that are active upstream from the missing sup-
ressor gene. For instance, the tumor suppressor forkhead box 0
FOX0) normally causes apoptosis. If FOX0 is inactivated in can-
er, an unopposed pathway upstream from it is the PI3K/Akt1
ignaling pathway, which could alternatively be targeted [53].
he mitogen-activated protein kinase/extracellular-signal regu-
ated kinase/mitogen/extracellular signal-regulated kinase (MEK)
athway, however, can act as a substitute or compensatory path-
ay to PI3 K/Akt1. So, in order to effectively shut down replication,
t would seem necessary to address these pathways as well.
Cancer-related signaling pathways, including even those that
ecome driver pathways, may  be epigenetically modiﬁed prior to
heir genetic modiﬁcation in cancer pathogenesis [54]. This sug-
ests an emphasis on chemoprevention or treatment of very early
ancers. Targeting may  be more straightforward to achieve under
hese conditions, since it is easier to modulate wild-type pathways
harmacologically than to treat the consequences of the onset of
idespread aneuploidy. In this case, the cancer phenotype may
ell precede the cancer genotype by years or more. Combining
nowledge of genetic and epigenetic changes in a particular tumor
ay  result in the targeting of key pathways with fewer agents and
educed cost.
A more general consideration is that both direct and indirect tar-
ets and approaches can be considered. Direct targets are those that
re familiar to us from targeted therapies – oncogenes, tumor sup-
ressor genes, signaling pathways. Indirect approaches, however,
re also potentially useful. For instance, evasion of the immune
ystem is a hallmark of cancer [27], and immunomodulatory tar-
ets and approaches are appropriate to support the capacities
f immune cells to eliminate tumor cells. Immune regulators
re, in a sense, inherently multi-targeted due to the complexity
f the responses they induce [55]. However, immunity is fre-
uently compromised in patients under treatment with cytotoxic
hemotherapies, as well as in the post-surgical period. ImmuneBiology 35 (2015) S276–S304
system approaches that also support the capacity of patients to
tolerate or recover from surgery or toxic therapies indirectly sup-
port the health of cancer patients [56]. The potency of the immune
system is illustrated by ﬁndings that chemotherapy may  enhance
antitumor immunity if given in the correct sequence, and that can-
cer refractory to chemotherapy or immune modulation alone may
become susceptible to both together [57].
2.1.2. Selection of approaches
The need for low-toxicity agents as constituents suggested
that phytochemicals – especially those “pre-screened” in humans
owing to their presence in foods or traditional medicines – should
be carefully considered during approach selection. Each hallmark
team therefore included cancer researchers who had consider-
able experience working with phytochemicals. In considering
phytochemicals and other low-toxicity agents for inclusion in a
broad-spectrum approach, however, several limitations in the lit-
erature promptly become clear.
First, the level of evidence for the effects of natural products on
particular hallmark targets varies widely. The status of laboratory
studies and clinical trials on several well-known phytochemi-
cals, e.g. resveratrol, epigallocatechin gallate (EGCG), curcumin,
lycopene and others, was  recently reviewed [58]. The pleiotropic
nature of the effects of these agents on apoptosis and arrest of
cell growth has been emphasized, and their potential use in asso-
ciation with chemotherapy drugs has been acknowledged. Novel
strategies based on a strategic combination of phytochemicals with
broad-spectrum action together with radiation or chemotherapy
agents aimed at overcoming resistance to apoptosis and enhancing
sensitivity to treatment are also currently being considered [59,60].
Second, considerable clinical experience with combinations of
phytochemicals and other natural agents in treatment of cancer
patients exists. Detailed knowledge of the pharmacological effects
of combinations of phytochemicals, however, is limited. There is
a large literature on herbal combinations used in traditional Chi-
nese medicine in both the laboratory and clinic [61–63], but the
quality of older clinical trials is generally low. Additionally, lab-
oratory studies of herbal medicines often use concentrations far
higher than are clinically achievable. Supra-physiological concen-
trations can produce artifactual or irrelevant mechanisms of action
or cause toxicity. The limited bioavailability of major phytochem-
icals makes this especially concerning, although products with
improved bioavailability are in development [64]. In general, phy-
tochemical research merits rigorous attention if we hope to gain
a more detailed understanding of how these compounds affect
the cancer hallmarks. Basic research needs to be followed up with
better-designed, statistically powered clinical trials, if we hope to
fully realize the therapeutic potential of phytochemicals.
In addition to laboratory studies and clinical trials, approaches
may  be suggested by epidemiological studies and the observations
of integrative medicine, which uses diet and lifestyle therapies
to affect medical conditions including cancer. Observational stud-
ies of soy consumption, along with corroborating evidence from
clinical studies, suggest that dietary consumption of soy foods
consistent with levels in the Japanese diet (2–3 servings daily, con-
taining 25–50 mg  isoﬂavones) may be associated with reduced risk
of breast cancer incidence and mortality [65]. However, ﬁndings
from animal studies [66] of negative effects of the soy isoﬂavone
genistein on breast cancer and its treatment suggest some caution
and avoidance of simplistic recommendations.
At all levels of investigation, the multi-targeted nature of phy-
tochemicals as well as the integrative therapies is notable. Manytargets through multifaceted effects on physiology and metabolism
[67–69]. A basic complication of these multi-targeted agents,
however, is the lack of mechanistic understanding and scientiﬁc
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cceptance of the roles of synergistic or additive molecules in for-
ulation. Although used by human populations for millennia, there
emains a question of how to develop and assess multi-component
atural product formulations that are suitable for large-scale pro-
uction. Genome-wide screening for assessment of targeted effects
nd experimentation with formulation of some herbs typical of tra-
itional Ayurvedic medicine have recently been attempted in Asian
aboratories, and are examples of attempts to better understand
ffects of multi-component agents [70–72].
. Hallmarks of cancer
In this section we provide brief summaries of each hallmark
eview included in this special issue of Seminars in Cancer Biology.
ach summary includes the targets and approaches selected in the
allmark review. Tables summarizing the targets and approaches
nd discussion of the cross-validation results follow. In addition, a
ummary of the impacts of integrative therapies on cancer-related
olecular targets follows the hallmark summary material.
The hallmark summaries are roughly sequenced to capture the
cquired capabilities of most cancers (see Fig. 2). The section begins
ith genomic instability,  an enabling characteristic, followed by sus-
ained proliferative signaling and evasion of anti-growth signaling,
wo hallmarks that ensure that proliferation is unabated in cancer
ells. These are followed by resistance to apoptosis and replicative
mmortality, two layers of defense that are believed to be bypassed
n all cancers. Then we discuss dysregulated metabolism andre acquired by most cancers, as portrayed in the graphical representation of tumor
tumor-promoting inﬂammation, which signal an important self-
reinforcing evolution in the tumor microenvironment. Sections on
angiogenesis and tissue invasion and metastasis speak to disease pro-
gression. Finally the tumor microenvironment and immune system
evasion summaries relate to the last lines of defense to be defeated
in most cancers.
3.1. Genomic instability
Genomic instability plays a critical role in cancer initiation and
progression. It provides the means by which a cell or subset of cells
acquire a selective advantage over neighboring cells, enabling out-
growth and dominance in the tissue microenvironment. In normal
cells, the ﬁdelity of the genome is protected at every stage of the cell
cycle by checkpoints. In cancer, the presence of aneuploid cells indi-
cates the failure of one or more of these checkpoints. The resulting
genomic heterogeneity may  offer the cancer “tissue” growth advan-
tages under selective pressures, including hypoxia, immune- and
therapy-related challenges. Understanding these checkpoints, and
how they are bypassed in cancer cells, may  provide opportunities
for the development of rational combinatorial or broad-spectrum
treatment strategies, including nutraceuticals such as resveratrol
[73,74].A cell, either transformed or normal, must pass through multi-
ple checkpoints during the process of division. These checkpoints
are operated by functional complexes of proteins that either enable
the cell to pass through the checkpoint (e.g. proto- or oncogenes) or
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revent the progression through the cell cycle (i.e. tumor suppres-
ors). The abundance of these proteins, and their functionality, can
e modiﬁed by genetic changes to their encoding sequences or by
on-genetic, or epigenetic, changes that regulate their abundance.
rieﬂy, small changes to the genes that encode proto-oncogenes or
umor suppressors will positively or negatively impact the func-
ion of the gene products. These small changes can be induced by
nvironmental and lifestyle factors, such as toxic substances, diet,
nd smoking, or they can be encoded in the individual at concep-
ion. In the case of DNA damage generated by the environment, it
s important that the cell repairs the damage effectively. Dysfunc-
ion in the molecules that come together to recognize and respond
o sites of damage is often associated with human cancer. Thus,
n understanding of the genetic or epigenetic status of DNA repair
enes, and of the nutraceuticals that may  modulate them [75], pro-
ides an opportunity to predict, detect, prevent and treat a variety
f human cancers.
Growing evidences show that vitamins, minerals, and other
ietary factors have profound and protective effects against can-
er cells, whether they are grown in the lab, in animals, or
tudied in human populations. We have identiﬁed ﬁve targets
gainst genomic instability: (1) prevention of DNA damage; (2)
nhancement of DNA repair; (3) targeting deﬁcient DNA repair; (4)
mpairing centrosome clustering; and, (5) inhibition of telomerase
ctivity. Vitamins D and B, selenium, carotenoids, PARP inhibitors,
esveratrol, and isothiocyanates are priority approaches against
enomic instability; these approaches may  dampen other enabling
haracteristics of tumor cells, such as replicative immortality, eva-
ion of anti-growth signaling, tumor promoting inﬂammation, and
ncogenic metabolism [73,76–82].
.2. Sustained proliferative signaling
Proliferation plays an important role in cancer development
nd progression, as manifested by altered expression and activity
f proteins related to the cell cycle [83,84]. Constitutive activa-
ion of a large number of signal transduction pathways takes
lace in cancer; this also stimulates cell growth. Early in tumor
evelopment a ﬁbrogenic response is often seen. Along with the
evelopment of a hypoxic environment [85,86], this favors the
ppearance and proliferation of cancer stem cells (CSCs). The
urvival strategies distinguishing CSCs from normal tissue stem
ells involve lack of cellular differentiation and alterations in
ell metabolism, such as higher antioxidant levels [83,84]. These
lterations take place as cells adapt to the changing microen-
ironment in affected tissue, prior even to the appearance of
umors. A part of this adaptation embodies epigenetic and genetic
lterations in gene expression [6,87] that also confer resistance
o many cytotoxic treatments [88,89]. Thus, adaptive resistance
s likely acquired early in the pathogenesis of many tumor
ypes.
Once tumors appear, the continued selection of cells with
ustained proliferative signaling further promotes tumor hetero-
eneity. This is accomplished by growth and metastasis, which
ay be supported by overproduction of appropriate hormones (in
ormonally dependent cancers), by promoting angiogenesis, by
ndergoing EMT, by altering the balance between apoptosis, necro-
is and autophagy, and by taking cues from surrounding stromal
ells. A number of natural compounds (such as EGCG) have been
ound to inhibit one or more pathways that contribute to prolif-
ration [90–92]. Many of these compounds are nontoxic at doses
hat inhibit tumor growth and/or prevent the appearance of tumor.
owever, one of the keys to their efﬁcacy involves their earliest pos-
ible therapeutic application. This is because their efﬁcacy is likely
o be the greatest in target tissues prior to the appearance of a tumor
here cellular heterogeneity is the least. In addition, many of theBiology 35 (2015) S276–S304
steps in carcinogenesis prior to tumor appearance are epigenetic in
nature, and are more easily targeted by existing compounds, most
of which target wild type molecules. This approach limits adap-
tive resistance, since early intervention does not have to deal with
the issues of aneuploidy, loss of heterozygosity in multiple tumor
suppressor genes, and point mutations in oncogenes. The contri-
bution of bioinformatics analyses will be important for identifying
signaling pathways and molecular targets that may provide early
diagnostic markers and/or critical targets for the development of
new drugs or combinations that block tumor formation. Thus, early
intervention in pathways and molecules that mediate sustained
proliferative signaling will limit adaptive resistance because it tar-
gets cells in tissues that have limited genotypic and phenotypic
heterogeneity.
Targets selected for sustained proliferative signaling are
hypoxia-inducible factor-1 (HIF-1) signaling, NF-B signaling,
PI3K/Akt signaling, wingless-type mouse mammary tumor inte-
gration site (Wnt) (-catenin) signaling, insulin-like growth factor
receptor (IGF-1R) signaling, cell cycle [cyclin-dependent kinases
(CDKs)/cyclins], androgen receptor signaling, and estrogen recep-
tor signaling. Possible therapeutic approaches include curcumin,
genistein and resveratrol.
3.3. Evasion of anti-growth signaling
Normal cells must acquire the ability to continuously prolifer-
ate in order to transform into malignant phenotypes. However,
cells have internal programs (anti-growth signaling) to oppose
limitless growth. In order to continue to proliferate, cancer cells
must somehow evade many anti-growth signals. In general, anti-
growth signaling is mediated by the activation of tumor suppressor
genes. The Cancer Genome Atlas has compiled data encompassing
all tumor types, which indicates that p53 is the most frequently
mutated tumor suppressor gene followed by PTEN, APC, ATM,
BRCA2, VHL, RB,  CDKN2A, BRCA1 and WT1.
Retinoblastoma protein 1 (RB1) was  the ﬁrst identiﬁed tumor
suppressor and deletion of this gene is frequently found in cancers
[93]. In many cases, the loss of RB is due to defects in upstream
signaling molecules such as inactivation of INK4. Loss of p16ink4a
results in unopposed activation of CDK4/6, which phosphorylates
the RB protein thereby activating E2F-mediated transcription of
genes involved in entry into the cell cycle [94].
Another tumor suppressor frequently deleted due to chromo-
somal loss is p53 [95]. In fact, more than 50% of all tumors have
loss of p53 tumor suppressive functions. Recently, mutant p53 has
gained renewed attention due to the fact that along with the loss of
tumor suppressive functions, mutant p53 gains oncogenic/tumor
promoting functions [96].
Epigenetic silencing of tumor suppressor proteins, which
includes DNA methylation, histone methylation and acetylation,
is another mechanism through which tumor cells evade anti-
growth signaling. Many tumor suppressor genes have been found
to have promoter hypermethylation in cancers [97]. Finally, anti-
growth signaling plays a major role in treatment response and drug
development. For example, the patients with human papilloma
virus-positive oropharyngeal cancer mostly retain wild-type p53
and have better prognosis and survival.
Although genetic alterations are mostly irreversible, epige-
netic repressions are potentially reversible and targets for drug
development. At least three histone deacetylase inhibitors, beli-
nostat, vorinostat and romidepsin, are currently approved by the
US FDA for cancer treatment. Many natural compounds also target
the restoration of tumor suppressors through modifying epige-
netic changes [98–102]. Thus, approaches to activate anti-growth
signaling will open another chapter for cancer prevention and
therapy.
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The prioritized targets for anti-growth signaling are RB, p53,
hosphatase and tensin homolog (PTEN), Hippo, growth differen-
iation factor 15 (GDF15), AT-rich interactive domain 1A (ARID1A),
otch, IGF-1R and others. The approaches are inactivation of E2F
y down regulation of pRb using CDK inhibitors, activation of
53 through up-regulation of wild-type p53, activation of PTEN
o inhibit PI3K-AKT, activation of Hippo pathways by inhibiting
es-associated protein/transcriptional enhancer activator domain
YAP/TEAD) activity, induction of GDF15 through p53 activation,
ctivation of ARID1A, blocking Notch pathway, and inhibition of
GF-1R to restore tumor suppressor pathways. Suggested phy-
ochemicals for these approaches are EGCG, luteolin, curcumin,
enistein, resveratrol, withaferin A, and deguelin. Furthermore,
hile the evasion of anti-growth signaling is a critical hallmark
f cancer, other hallmarks are similarly important and a more
ntegrative approach is necessary to simultaneously target several
allmarks of cancer to combat this deadly disease.
.4. Resistance to apoptosis
Apoptosis naturally removes aged and unhealthy cells from
he body [103]. However, in cancer, cells lose their ability to
ndergo apoptosis leading to uncontrolled proliferation and mul-
iplication. These malignant cells are often found to overexpress
any of the proteins that play important roles in resisting the
ctivation of the apoptotic cascade, and one of the major hall-
arks of human cancers is the intrinsic or acquired resistance
o apoptosis [104]. Evasion of apoptosis may  contribute to tumor
evelopment, progression, and also to treatment resistance, since
ost of the currently available anticancer therapies including
hemotherapy, radio- and immunotherapy primarily act by activat-
ng death/apoptotic pathways in cancer cells [105]. Hence, a better
nderstanding of the molecular mechanisms underlying tumor
esistance to apoptotic cell death is expected to provide the basis
or a rational approach to develop molecular targeted therapies.
Apoptosis resistance is multi-factorial and emanates from the
nteractions of various molecules and signaling pathways at mul-
iple levels. Several mechanisms exist allowing cells to escape
rogrammed cell death. Among them is the overexpression of the
nti-apoptotic molecules. B-cell lymphoma-2 (Bcl-2) family pro-
eins play a critical role in the biology of apoptosis resistance.
obust agents against the Bcl-2 homology domain 3 proteins are
n development and accelerating toward clinical application. Other
ell death mechanisms such as autophagy and necrosis can also
e highlighted and strategies against them exist, including the
se of natural agents such as EGCG. The role of the chaperone
rotein heat shock protein 70 (Hsp70) in apoptosis resistance
s important, and natural agents may  also address this. Various
olecular mechanisms support resistance to apoptosis in differ-
nt disease models such as glioblastoma, multiple myeloma and
hronic lymphocytic leukemia. Epigenetic players, particularly the
on-coding RNAs/microRNAs, are also of importance. Novel targets
an be pinpointed, such as ecto-nicotinamide dinucleotide disul-
de thiol exchanger protein (ENOX) and nuclear export protein
hromosomal regional maintenance protein 1(CRM1), along with
peciﬁc strategies to overcome these important drug resistance
romoters. Other targets include inhibition of Mcl-1, activation
f tumor autophagy, activation of tumor necrosis, inhibition of
sp90, inhibition of proteasomes, and inhibition of EGFR and Akt.
pproaches to these targets include gossypol, UMI-77, EGCG, trip-
olide, PXD, selinexor, and inhibitors of EGFR and Akt. Collectively,
he knowledge gained through greater understanding of the apo-
tosis resistance targets and speciﬁc strategies is anticipated to
ring forward a broad form of therapy that could result in bet-
er treatment outcome in patients suffering from therapy-resistant
ancers.Biology 35 (2015) S276–S304 S287
3.5. Replicative immortality
Replicative immortality, the ability to undergo continuous self-
renewal, is necessary for propagation of normal germ cells, but is
not a property of normal somatic cells. When acquired by somatic
cells that have sustained genetic damage or instability, replica-
tive immortality allows accumulation of sequential aberrations
that confer autonomous growth, invasiveness, and therapeutic
resistance [106]. As a result, several mechanisms have evolved to
regulate replicative potential as a hedge against malignant progres-
sion [107]. Senescence, a viable growth arrest characterized by the
inability of affected cells to resume proliferation in the presence of
appropriate mitogenic factors, is a speciﬁc response to the grad-
ual shortening of chromosomal end structures (telomeres) with
each round of cell replication, and a more general response to onco-
genic and genotoxic stresses. Senescence often involves convergent
interdependent activation of tumor suppressors p53 and p16/pRB
[108,109], but can still be induced, albeit with reduced sensitiv-
ity, when these suppressors are inactivated. Doses of conventional
genotoxic drugs required to achieve cancer cell senescence are
often much lower than doses required to achieve outright cell
death [110]. Additional targeted therapies may  induce senescence
speciﬁcally in cancer cells by blocking cyclin-dependent kinase
mediated inhibition of RB-family proteins [111], or by exploiting
cancer cells’ heightened requirements for maintenance of telomere
length through the action of the enzyme telomerase [112]. Develop-
ing optimized and truly holistic cancer prevention and treatment
regimens will likely incorporate strategies that target replicative
immortality.
The chief advantage to be gained by the use of senescence-
inducing therapeutic regimens is elimination of the tumor’s
repopulating ability with reduced collateral damage compared to
conventional cytotoxic regimens. There are, however, certain ques-
tions and risks associated with this strategy that must be addressed
before its clinical adoption. In the case of telomere and telomerase
based strategies, replicative senescence may  occur more readily
in rapidly dividing cancer cells bearing short telomeres than in
slowly dividing stem cells with comparatively longer telomeres,
but telomere lengths in cancer cells may  still be long enough to per-
mit  sufﬁcient population doublings for invasion and metastases to
occur [112] Moreover, telomere dysfunction promotes the devel-
opment of chromosomal instability, which in turn can generate
mutations that enable cells to become drug resistant and/or acti-
vate mechanisms based on alternative lengthening of telomeres
for telomere maintenance and/or become more malignant [113].
High priority should therefore be given to further research into the
determinants of senescence stability, as the implications of delayed
cell cycle re-entry, permanent cytostasis, or eventual clearance may
be profoundly different. Lower doses of genotoxic drugs needed to
induce senescence may  reduce collateral damage to critical nor-
mal  cells, but allow establishment of dormancy and/or adaptive
resistance by cancer cells. The microenvironmental and systemic
effects of senescent cells also need further clariﬁcation, as factors
secreted by senescent cells may  promote tumorigenic changes in
nearby cells. Conversely, since it is almost impossible to kill all
the cells in malignant tumors even using the highest tolerated
doses of chemotherapy, combined use of an agent that induces or
enhances stable senescence in the cancer cells that manage to retain
viability might additively or synergistically increase therapeutic
efﬁcacy.
A number of potential targets can be singled out for fur-
ther research, including telomerase, human telomerase reverse
transcriptase (hTERT), mammalian target of rapamycin (mTOR),
CDK4/6, CDK 1/2/5/9, Akt and PI3K. Several approaches deserve
further research, although the activity of the phytochemicals in
particular is still far from clinical utility. These include imetelstat,
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enistein, perillyl alcohol, palbociclib, dinaciclib, curcumin and
GCG.
.6. Dysregulated metabolism
Dysregulated metabolism is a hallmark of cancer in which many
ancer cells show increased glucose uptake and produce lactate.
his characteristic is often called the “Warburg effect” [114], but
ow and why cancer cells reprogram their metabolic state is not
ell understood. Recent research has focused on understanding the
etabolic changes accompanying oncogenesis [27]. A new model
f cancer metabolism positions metabolic rewiring in cancer as
 coordinated process to support rapid cellular proliferation by
uning cellular energy production needs toward biosynthetic pro-
esses. Indeed, several metabolic shifts associated with cancer can
e linked to cellular growth, which serve to support biosynthesis
f lipids, proteins, nucleic acids required for tumor formation and
urvival [115].
In several cases, expression of oncogenes and/or loss of tumor
uppressors lead directly to changes in metabolism, by expression,
ctivity, or ﬂux of key metabolic nodes. Several components of
lucose and glutamine metabolism have emerged as important reg-
lators of metabolism in cancer. In glucose metabolism, hexokinase
 (HK2), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3
PFKFB3) and pyruvate kinase isoform M2 (PKM2) all regulate gly-
olytic ﬂux. Using a “kitchen sink” analogy for glycolysis, both HK2
nd PFKFB3 are regulators of the faucet, and ﬁll up the sink. Con-
ersely, PKM2 regulates the drain. Cancer metabolism turns on the
aucet and plugs the drain, which over-spills the glycolytic path-
ay and provides metabolites used as building blocks for cellular
rowth. Efforts are underway to identify therapeutic strategies to
turn off the faucet” or “unplug the drain” in glycolysis, limiting cel-
ular growth in cancer. Recent studies have also determined that
lutamine is used as a fuel (glutaminolysis) in proliferating can-
er cells. Glutamine oxidation can provide carbon and nitrogen for
rowth, and therefore is an attractive therapeutic target in can-
er. Additionally, mutations in genes encoding enzymes directly
nvolved in metabolic pathways have been associated with sev-
ral types of cancer. Rather than acting as a bystander or facilitator
f oncogenesis, aberrant metabolism now has a pro-oncogenic role
nd has led to the redeﬁnition of some metabolites as ‘oncometabo-
ites’ [116]. Indeed, these oncometabolites are powerful inﬂuencers
f proliferation, and are also positioned as new therapeutic targets.
In principle, a broad-spectrum approach to target metabolic
hifts in cancer is likely to be a promising therapeutic strategy.
owever, studies using this approach to target dysregulated
etabolism in cancer are in their infancy. Lessons could be
earned from other strategies to target mitochondria or to target
etabolism in order to identify efﬁcacious and safe therapies
argeted at cancer metabolism; some drugs targeting metabolism
re being re-purposed for their antitumorigenic effects. Sev-
ral approaches could be mentioned, such as 3-bromopyruvate,
-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK-15), 6-[(3-
minophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulﬁnyl)-
H-thieno[2′,3′:4,5]pyrrolo[2,3-d]pyridazin-5-one (TEPP-46),
ichloroacetate, hexachlorophene, bis-2-(5-phenylacet-amido-
,2,3-thiadiazol-2-yl)ethyl sulﬁde (BPTES) and 2,3-Dihydroxy-
-Methyl-7-(phenylMethyl)-4-propyl-1-naphthalenecar-boxylic
cid (FX11), but data for these must be regarded as extremely
reliminary, and they lack sufﬁcient justiﬁcation to be included in
herapy without further study. Most target proteins or pathways
dentiﬁed as having potential to manipulate cancer metabolism
ave not been directly tested in the context of other hallmarks. The
merging efﬁcacy of physiological interventions that manipulate
ancer outcomes, such as fasting, calorie restriction, or exercise,
ould inﬂuence cancer metabolism and other hallmarks of cancerBiology 35 (2015) S276–S304
[117]. Future studies directly testing the ability to manipulate
dysregulated metabolism in cancer will be an important and
exciting new area of cancer biology that has potential for treating
a variety of cancers.
3.7. Tumor-promoting inﬂammation
Virchow ﬁrst proposed the role of inﬂammation in cancer in
1863, while observing the presence of leukocytes in neoplasms,
and empirical evidence has since underscored the importance
of this linkage [118,119]. The inﬂammatory milieu promotes a
cellular microenvironment that favors the expansion of genomic
aberrations and the initiation of carcinogenesis [120]. Chronic
inﬂammation is linked to various phases of tumorigenesis, such as
cellular proliferation, transformation, apoptosis evasion, survival,
invasion, angiogenesis and metastasis [121–123]. Inﬂammation is
also known to contribute to carcinogenesis through the genera-
tion of reactive oxygen species (ROS) and reactive nitrogen species
which can damage DNA at the site of the tumor [124]. Free radi-
cals and aldehydes, produced during chronic inﬂammation, can also
induce deleterious gene mutation and post-translational modiﬁca-
tions of key cancer-related proteins [125].
In addition, chronic inﬂammation has an inﬂuence on immune
system constituents that are directly linked with cancer pro-
gression. Under normal conditions, immune cells, including
macrophages, granulocytes, mast cells, dendritic cells, innate lym-
phocytes, and natural killer (NK) cells serve as the front line
of defense against pathogens. When tissue disruption occurs,
macrophages and mast cells secrete matrix-remodeling proteins,
cytokines and chemokines, which activate local stromal cells (e.g.,
ﬁbroblasts, adipocytes, vascular cells) to recruit circulating leuko-
cytes into damaged tissue (acute inﬂammation), to eliminate
pathogens [126]. However, when these processes are initiated in
the tumor microenvironment, they are not resolved, which leads to
chronic inﬂammation of the “damaged” (tumor) tissue. Thus, while
acute inﬂammation normally supports and balances two opposing
needs for the repair of damaged tissues (apoptosis and wound heal-
ing), chronic inﬂammation represents a loss of this balance and the
resulting conﬂuence of factors has deleterious implications for the
immune system [127].
Accordingly, the relationship between tumor-promoting
inﬂammation and cancer is important to consider. Macrophage
migration inhibitory factor, cyclooxygenase-2 (COX-2), NF-B,
tumor necrosis factor alpha (TNF-),  inducible nitric oxide syn-
thase (iNOS), Akt, and chemokines are important antiinﬂammatory
targets that might be suitable for a multi-pronged therapeutic
approach to inﬂammation suppression. Additionally, curcumin,
resveratrol, EGCG, genistein, lycopene, and anthocyanins are
forms of low-cost chemistry with little to no toxicity that could be
employed to reach these targets.
Future translational work should make use of promising agents
such as these (combined as constituents within a multi-pronged
antiinﬂammatory approach) bearing in mind that some of these
targets impact the immune system and can increase the risks asso-
ciated with infection. Bioavailability challenges are also a concern
for a number of these agents but recent advances in delivery sys-
tems will help address this issue.
3.8. Angiogenesis
Angiogenesis, the expansion of an existing vasculature, is the
main mechanism of blood vessel growth, and is therefore essential
for tumor development [128]. Tumor angiogenesis is switched on
by changing the balance between angiogenic factors and inhibitors
in favor of angiogenesis [129], a process induced by tumor hypoxia
as the tumor grows beyond a size of approximately a few mm3
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128,130]. At more advanced stages, progressive genomic insta-
ility in the tumor leads to mutations in pathways regulating
he production of multiple angiogenic factors [131], and stroma
ells also become important sources of sustained angiogenic factor
roduction [29]. These collectively result in a stronger and more
omplex angiogenic factor proﬁle. It is therefore not surprising
hat targeted neutralization of a single angiogenic factor, which
as been the focus for antiangiogenic cancer therapy so far, rarely
roduces long-term antitumor effects [29].
Due to the multifactorial nature of tumor angiogenesis this pro-
ess is likely to be more efﬁciently treated by targeting multiple
spects of tumor angiogenesis and vascular dysfunction at the
ame time. Ten of the most important targets for tumor angio-
enesis and vascular dysfunction are to inhibit endothelial cell
igration/tip cell formation, reduce structural abnormalities of
umor vessels, reduce hypoxia, inhibit lymphangiogenesis, reduce
levated interstitial ﬂuid pressure, reverse poor perfusion, nor-
alize disrupted circadian rhythms, suppress tumor-promoting
nﬂammation, deactivate tumor-promoting ﬁbroblasts and nor-
alize tumor cell metabolism/acidosis.
Currently available non-speciﬁc antiangiogenic agents, able to
erform some of these tasks, are however quite toxic, which ren-
ers them unsuitable for long-term use [131–133]. There is an
rgent need to identify alternative compounds that could be used
n combination over extended periods of time, targeting tumor
ngiogenesis broadly and thus lowering the risk of resistance. Plant-
erived compounds, phytochemicals, are in many cases better
olerated than the synthetic analogs used in cancer therapy today.
urthermore, they often exhibit broader mechanisms of action and
ometimes even higher afﬁnity against important cancer targets
ompared to the synthetic alternatives [134]. Ten phytochemicals
hat may  be effective as approaches to neutralize the 10 identi-
ed targets are oleanoic acid, tripterine, silibinin, curcumin, EGCG,
aempferol, melatonin, enterolactone, withaferin A and resvera-
rol. Further study is needed to determine the optimal use and
ombination of these phytochemicals in antiangiogenic therapy,
ocusing on delivery, toxicity and their use in prophylactic regi-
ens.
.9. Tissue invasion and metastasis
Cancer causes substantial patient morbidity and mortality glob-
lly, making it a key health issue. Metastatic dissemination of the
isease to distant sites impacts prognosis, with metastatic dis-
ases accounting for a vast percentage of cancer patient mortality
27,135,136]. Cancer cells must overcome particular obstacles in
rder to successfully disseminate to and establish at a secondary
ocation, progressing through the metastatic cascade. Successful
rogression through this cascade is linked with numerous estab-
ished changes in cellular functions leading to the acquisition
f an invasive phenotype. This involves loss of cell-cell contact
ith the main tumor body, invasion, degradation and migration
hrough surrounding tissue and extracellular matrix, secretion
f angiogenic/lymphangiogenic factors and intravasation to the
lood/lymph vessel, transport around the body and evasion of the
mmune system, extravasation at the secondary site and establish-
ent of a secondary tumor [137,138].
Hence, factors inﬂuencing these processes such as cell adhe-
ion molecules, proteolytic matrix degrading enzymes, cell motility
nd factors involved in the process of EMT  have all been subject to
cientiﬁc scrutiny. Additionally, the complex heterogeneity within
umors, together with cellular interactions between tumor cells
nd other, non-cancerous, cell types have been established to play
ey roles in metastatic dissemination and add further complex-
ty to this cascade [136,137]. While advances in the ﬁeld of cancer
esearch have been made, the process of cancer metastasis and theBiology 35 (2015) S276–S304 S289
factors governing cancer spread and establishment at secondary
locations are still poorly understood. Current treatment regimes
for metastatic disease pose many adverse effects, which can further
negatively impact on a subset of patients generally presenting with
poorer health conditions. Hence there is a great need to develop
new therapeutics that not only target tumor growth and inhibit
metastasis but that also have a lower toxicity and reduced inherent
side effects. Factors associated with metastasis such disruption of
E-cadherin and tight junctions, key signaling pathways, including
urokinase-type plasminogen activator, PI3K/AKT, focal adhesion
kinase, -catenin/zinc ﬁnger E-box-binding homeobox 1 and trans-
forming growth factor (TGF)-,  together with inactivation of activa-
tor protein 1 (AP-1) and suppression of matrix metalloproteinase-
9 (MMP-9) activity should be considered as key research
priorities.
The need can also be highlighted for new, low toxicity
compounds, which interfere with these processes but remain
inexpensive alternatives that are readily available and free from
intellectual property. Phytochemicals, or natural products, such as
those from Agaricus blazei, Albatrellus conﬂuens, Cordyceps militaris,
Ganoderma lucidum, Poria cocos and Silybum marianum,  together
with diet-derived fatty acids gamma-linolenic acid and eicosapen-
taenoic acid and inhibitory compounds have potential to inhibit
these key metastatic events. These potential targets and strategies
thus present new therapeutic opportunities to both manage can-
cer metastasis as well as having holistic effects against many of the
hallmarks of cancer.
3.10. Tissue interactions in the tumor microenvironment
Cancer arises in an in vivo tumor microenvironment. This
microenvironment is a cause and consequence of tumorigenesis,
and consists of cancer cells and host cells that co-evolve dynam-
ically through indirect and direct cellular interactions, producing
metabolites and secreting factors that affect cancer progression
[139,140]. In turn, this environment regulates the ability of a can-
cer to grow and survive via multiscale effects on many biological
programs including cellular proliferation, growth and metabolism,
as well as angiogenesis and hypoxia, innate and adaptive immu-
nity [141]. Speciﬁc biological programs could be, based on our
most recent understanding, exploited as targets for the prevention
and therapy of cancer, including: the inhibition of cholesterol syn-
thesis and metabolites, ROS and hypoxia, macrophage activation
and conversion, regulation of dendritic cells, regulation of angio-
genesis, ﬁbrosis inhibition, endoglin, and cytokine signaling. These
programs emerge as examples of important potential nexuses in
the regulation of tumorigenesis and the tumor microenvironment
that can be targeted.
Potential targets include metabolic programs that may  broadly
inﬂuence many cell biology programs that impact tumorigen-
esis and the tumor microenvironment (cholesterol synthesis
and metabolites, ROS and hypoxia), inﬂammation, innate and
adaptive immunity-related programs (macrophage conversion,
dendritic cell activation, immune signaling), host microenviron-
ment associated cellular programs (ﬁbrosis, angiogenesis), and
cytokine-mediated regulatory programs (IL-6, endoglin, and JAK).
We have particularly focused on identifying approaches for inhib-
iting these targets that included natural products that have been
suggested to have signiﬁcant anticancer activity. Some of these
molecules may  more generally inﬂuence tumorigenesis and the
microenvironment (berberine), others more speciﬁcally target
ROS (resveratrol, desoxyrhapontigenin), macrophage conversion
(onionin A), indoleamine 2,3-dioxygenase (IDO) regulation of
dendritic cells (EGCG), cholesterol synthesis (genistein), ﬁbrosis
(naringenin), inﬂammation and immune signaling (piperine) and
JAK signaling (zerumbone). This approach will provide a starting
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oint for examining synergies that might be anticipated in testing
ertain targets and/or mixtures of natural chemical constituents
hat may  modulate the tumor microenvironment in the treatment
nd prevention of cancer.
.11. Immune system evasion
Tumors evade immune attack by several mechanisms includ-
ng generation of regulatory cells and their secretions, defective
ntigen presentation, induction of immune suppressive mediators
ither by cancerous cells themselves or by those in the microenvi-
onment, tolerance, immune deviation and apoptosis.
Current approaches to immune therapy include (a) cellular tar-
ets, (b) molecular targets, (c) vaccination therapy, (d) therapy by
hytochemicals, (e) adoptive T cell therapy and (f) immunomodu-
atory antibodies. Of these anticancer agents, the most important
re those that are targeted in nature and to lesser extent, those
hat are non-speciﬁc in nature. Targeting speciﬁc costimulatory
olecules such as cytotoxic T-lymphocyte-associated protein-4
CTLA-4) [142] or programmed cell death protein (PD1/PD-L1)
143] is considered an important anticancer strategy. Also, anti-
D-1 antibodies are showing enormous therapeutic potential in
dvanced cancers. Targets that are considered appropriate for
road-spectrum, low-toxicity therapeutics are less speciﬁc and
nclude enhancing Th1 responses, enhancing  T cells, activation
f macrophages, inhibition of Treg lymphocytes, enhancing natural
iller cell activity and induction of IL-12.
There are a number of important nonspeciﬁc anticancer agents
hat have been reported, including vaccination therapy, as well
s nonspeciﬁc bacteria-based therapies [144], and phytochemicals
145–147]. Phytochemicals (the biologically active components of
ruits and vegetables) have been shown to exert protective effects
gainst cancer. Examples of potential phytochemical approaches
nclude extracts of Ganoderma lucidum, Trametes versicolor,  Astra-
alus membranaceus,  and Lentinus edodes,  as well as astaxanthin
nd the polyphenol resveratrol analog HS-1793. There is, however,
 downside to phytochemical therapy such as their poor absorp-
ion by humans and rapid metabolism and excretion. More work is
equired to assess which phytochemicals block evasion of immune
urveillance and also to determine which phytochemicals promote
ntitumor responses in cancer patients before these can be recog-
ized for therapeutic value in the clinic.
. Summary of ﬁndings on targets and approaches in
allmark reviews
As described above, a cross-validation process was employed
o review the proposed actions on each target and all of the
pproaches for known effects on other hallmark areas and
he tumor microenvironment. Anticarcinogenic synergies and
onfounding/procarcinogenic effects were then compiled and
ummarized in Tables 1–3. Supplemental Table S1, a sample cross-
alidation table for dysregulated metabolism approaches, was used
n construction of Tables 2 and 3. Supplemental Tables S2 and S3
ontain the aggregated cross-validation tables from each review
with references omitted). More detailed discussion of these inter-
ctions can be found in the individual hallmark reviews.
Table 1 shows an alphabetical listing of prioritized targets from
ach hallmark review, as well as the number of contrary, con-
roversial, none known and complementary interactions with all
ther hallmarks. Dysregulated metabolism targets do not appear
n the table; too little is known about the targets in this new area
f research to reliably assess their interactions with other hall-
arks. Of these relationships, 3.98% were contrary, 7.62% wereBiology 35 (2015) S276–S304
controversial, 21.74% of interaction assessments found no known
relationship, and 66.71% were complementary.
Table 2 shows the prioritized therapeutic approaches–the phy-
tochemicals, plant extracts and drugs chosen as modiﬁers of the
priority targets. Of these, 1.08% were contrary, 7.62% were con-
troversial, 34.05% had no known relationships and 62.1% were
complementary. Both contrary and controversial interactions indi-
cate potential conﬂict among the targets and approaches selected
for different hallmarks that could result in a broad-spectrum
approach with antagonistic, rather than synergistic effects.
The small number of contrary and controversial interactions is
encouraging, and suggests that the potential for negative interac-
tions among the selected targets and approach may be limited.
However, this may  also reﬂect the common bias in the literature to
publish positive antitumor effects. Nearly a third of potential inter-
actions were listed as having no known relationship, suggesting the
need for substantially more research in this area. The large number
of complementary interactions is also encouraging but may  result
from indirect or bystander effects.
Table 3, in which the different types of interactions of both
targets and approaches are listed for each hallmark, reﬂects dif-
ferent levels of knowledge regarding hallmarks, as well as varying
prevalence of complementary approaches. Genomic instability has
the largest number of unknown relationships with the targets and
approaches. On the other hand, tumor microenvironment, tissue
invasion and metastasis and resistance to apoptosis have the high-
est number of complementary interactions for both targets and
approaches. Small numbers of contrary interactions were found
for the different hallmarks for both targets and approaches, but
the number of targets for replicative immortality and angiogene-
sis, reﬂecting mixed positive and negative interactions, were larger
than for other hallmarks.
There are a number of limitations that should be noted in this
delineation of cross-hallmark relationships. First, the researchers
who assembled these results were not asked to distinguish between
direct effects on other hallmark areas and reported effects on other
hallmark areas that may  have resulted in an indirect or “bystander”
effect mediated through a different mechanism. In many cases, but
not all, this distinction was made. Therefore it is likely that some of
the complementary interactions do not represent a fully indepen-
dent cross-hallmark relationship, but rather are simply indicative
of some sort of downstream effect (e.g., within a signaling cas-
cade or via some other signaling molecule that exerts pleiotropic
effects). However, we  did not feel that this project needed to inves-
tigate the nature of these complementary interactions in detail,
especially since the clinical impacts of these interactions would be
similar for indirect and direct effects. Instead, our main concern was
focused on the possibility that a large number of cross-hallmark
relationships might be revealed where actions with procarcino-
genic or tumor-promoting potential had been reported. It was  more
important to identify contrary and controversial cross-hallmark
interactions than complementary ones, since targets or approaches
that exert procarcinogenic actions would normally need to be more
carefully assessed (or avoided altogether) in the development of
combination approaches or interventions.
The second limitation of these reports of cross-hallmark rela-
tionships is related to data quality. In some instances, the available
evidence used to support the indication of a cross-hallmark rela-
tionships was  robust, consisting of multiple studies involving
detailed in vitro and in vivo ﬁndings. In other instances, however,
the underlying evidence that was used to report the existence of
a cross-hallmark relationship was  quite weak (e.g., consisting of
only a single in vitro study involving a single cell-type). Again, the
overarching goal in this project was  to create a foundation that
would allow us to look systematically across the literature in each
of these areas, to help us shape the selection of the targets and
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Table  1
Prioritized targets with summary of information from cross-validation tables.
Hallmarka,b Target (action on target) Contrary Controversial Complementary None known
AP, RI, TPI Akt (inhibit) 0 0 11 0
SPS  Androgen receptor signaling (suppress) 0 2 8 1
TIM  AP-1 (inhibit) 1 RI 0 7 3
EAG  ARID1A (activate) 1 TIM 0 5 5
AP  Bcl-2 (inhibit) 0 1 9 1
RI  CDK 1/2/5/9 (inhibit) 1 TME 0 9 1
RI  CDK 4/6 (inhibit) 1 GI 1 8 1
SPS  Cell cycle (CDKs/cyclins) (attenuate) 2 IS, TIM 0 9 0
GI  Centrosome clustering (block) 0 0 8 3
TME  Cholesterol metabolites (inhibit) 0 0 7 4
TME  Cholesterol synthesis (inhibit) 0 1 8 2
TPI  COX-2 (inhibit) 1 AN 0 10 0
TPI  CXC chemokine (inhibit) 0 3 5 3
AN  Disturbed circadian rhythms (normalize) 0 2 9 0
GI  DNA damage (prevent) 1 TPI 3 5 2
GI  DNA repair (enhance) 1 TPI 3 5 2
EAG,  TIM E-cadherin (restore) 1 AN 4 4 2
EAG  E2F (inactivate) 1 TME 0 7 3
AP  EGFR (inhibit) 0 0 10 1
AN  Elevated interstitial ﬂuid pressure (reduce) 0 0 9 2
TME  Endoglin (inhibit) 0 1 5 5
AN  Endothelial cell migration/tip cell formation (inhibit) 0 0 7 4
AP  ENOX (inhibit) 0 0 5 6
SPS  Estrogen receptor signaling (suppress) 1 TIM 3 7 0
EAG  Endoplasmic reticulum stress (induce) 2 AN, TIM 1 7 1
TIM  FAK signaling (inhibit) 0 0 9 2
TME  Fibrosis (inhibit) 0 0 6 5
EAG  Growth differentiation factor 15 (induce) 1 GI 0 5 5
SPS  HIF-1 signaling (inhibit) 0 0 9 2
AP  Hsp90 (inhibit) 1 TIM 0 8 2
RI  hTERT (inhibit) 0 1 8 2
AN  Hypoxia (reduce) 0 1 10 0
TME  IDO (inhibit) 0 1 7 3
EAG,  SPS IGF-1R (inhibit) 0 0 9 2
IE  IL-12 (induce) 1 AP 0 5 5
TME  IL-6 (inhibit) 0 3 7 1
TPI  iNOS (block) 1 AN 1 6 3
TME  JAK (inhibit) 0 0 10 1
AN  Lymphangiogenesis (impede) 0 1 4 6
TME  M2 macrophage conversion (inhibit) 0 0 7 4
IE  Macrophages (activate) 2 SPS, TIM 2 3 4
AP  Mcl-1 (inhibit) 0 0 10 1
TPI  MIF (block) 0 0 9 2
TIM  MMP-9 (suppress) 0 1 7 3
RI  mTOR (inhibit) 0 2 8 1
SPS,  TIM, TPI NF-B signaling (inhibit) 0 2 8 1
IE  NK cell activity (promote) 0 0 7 4
EAG  NOTCH (block) 1 AN 0 8 2
AP  Nuclear exporter CRM1 (inhibit) 0 0 6 5
RI  PI3K (inhibit) 0 0 11 0
EAG,  SPS, TIM PI3K/Akt signaling (inhibit) 0 0 11 0
AN  Poor perfusion (improve) 0 1 7 3
AP  Proteasome (inhibit) 0 0 10 1
TME  ROS (inhibit) 0 2 7 2
AN  Structural abnormalities of vessel walls (inhibit) 0 0 7 4
GI  Target deﬁcient DNA repair 1 TPI 2 5 3
GI,  RI Telomerase (inhibit) 0 0 10 1
TIM  TGF- (inhibit) 1 RI 2 7 1
IE  Th1 response (promote) 1 TPI 0 5 5
TIM  Tight junctions (promote) 1 AN 0 6 4
TPI  TNF- (block) 1 IE 1 8 1
IE  Treg lymphocytes (inhibit) 0 1 6 4
AP  Tumor autophagy (activate) 1 TPI 4 4 2
AN  Tumor cell metabolism/acidosis (normalize) 0 0 9 2
AP  Tumor necrosis (activate) 2 AN, TME 3 5 1
AN  Tumor-promoting ﬁbroblasts (deactivate) 0 0 9 2
AN  Tumor-promoting inﬂammation (suppress) 0 0 7 4
TIM  Urokinase plasminogen activator (suppress) 1 RI 0 7 3
TME  VEGF (inhibit) 0 3 8 0
EAG  Wildtype p53 (upregulate) 0 0 10 1
SPS  Wnt (B-catenin) (inhibit) 0 3 7 1
EAG  YAP/TEAD activity (inhibit) 0 0 6 5
TIM  -catenin/ZEB1 (inactivate) 0 0 7 4
IE   T-cell activity (promote) 2 TPI, AN 0 4 5
Totals:  32 62 543 177
Percentages:  3.93% 7.62% 66.71% 21.74%
a For each target, the following items are shown: the hallmark(s) for which it was selected, and the number of other hallmarks with which it has complementary relationships, contrary
relationships,  no known relationships and controversial relationships. For targets that have contrary relationships, the conﬂicted hallmark(s) are shown. Totals and percentages of each
type  of relationship are shown at the end of the table.
b AN, angiogenesis; AP, resistance to apoptosis; DM, dysregulated metabolism; EAG, evasion of anti-growth signaling; GI, genomic instability; IE, immune evasion; RI, replicative
immortality;  SPS, sustained proliferative signaling; TIM, tissue invasion and metastasis; TME, tumor microenvironment; TPI, tumor promoting inﬂammation.
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Table 2
Prioritized approaches with summary of information from cross-validation tables.
Hallmarksa,b Approaches Contrary, conﬂicted hallmarks Controversial Complementary None known
DM 3-bromopyruvatec 0 0 7 4
TIM  5,6-dihydro-4H-pyrrolo[1,2-b]-pyrrazolesc 0 0 2 9
TPI  Anthocyanins 0 0 9 2
IE  Astaxanthin 0 0 7 4
IE  Astragalus membranaceus polysaccharide 1 AN 0 6 4
TME  Berberine 1 IE 0 9 1
DM  BPTESc 0 0 5 6
GI  Carotenoids 0 1 10 0
TIM  Cordycepin 0 0 8 3
AN,  EAG, RI, SPS, TME, TPI Curcumin 0 0 11 0
EAG  Deguelin 0 0 7 4
TME  Desoxyrhapontigenin 0 0 2 9
DM  Dichloroacetatec 0 0 7 4
RI  Dinacicilibc 0 0 6 5
AN,  AP, EAG, RI, TME, TPI EGCG 0 0 11 0
TIM  Eicosapentaenoic acid 0 0 8 3
AN  Enterolactone 0 0 7 4
DM  FX11c 1 GI 0 2 8
TIM  Gamma linolenic acid 0 0 7 4
TIM  Ganoderic acids 0 0 7 4
IE  Ganoderma lucidum polysaccharide 0 0 9 2
EAG,  RI, SPS, TME, TPI Genistein 0 5 6 0
AP  Gossypol 0 0 9 2
TIM  Grifolin 0 0 6 5
DM  GW5074c 0 1 3 7
DM  Hexachlorophenec 0 0 6 5
IE  HS-1793 (polyphenol resveratrol analog)c 0 0 5 6
RI  Imetelstatc 0 1 4 6
GI  Isothiocyanate 0 0 10 1
AN  Kaempferol 0 0 7 4
IE  Lentinus edodes polysaccharide 0 0 8 3
EAG  Luteolin 0 0 9 2
TPI  Lycopene 0 0 8 3
AN  Melatonin 0 0 10 1
DM  Metforminc 0 1 10 0
TME  Naringenin 0 2 6 3
AN  Oleanoic acid 0 0 10 1
TME  Onionin A 0 0 1 10
TIM  Pachymic acid 0 0 6 5
RI  Palbociclib c 1 TIM 0 4 6
GI  PARP inhibitorc 0 0 9 2
RI  Perillyl alcohol 0 0 10 1
TME  Piperine 1 IE 0 7 3
DM  PK15c 0 0 6 5
TIM  Polysaccharide (G. lucidum) 0 1 8 2
AN,  DM, EAG, GI, SPS, TME, TPI Resveratrol 0 2 9 0
GI  Selenium 1 TPI 2 6 2
AP  Selinexorc 0 0 3 8
AN,  TIM Silibinin 0 0 11 0
DM  TEPP-46c 0 0 3 8
IE  Trametes versicolor polysaccharide-k 0 0 3 8
AN  Tripterine 0 0 5 6
AP  Triptolide 1 IE 0 9 1
AP  UMI-77c 0 0 5 6
GI  Vitamin B 0 2 3 6
GI  Vitamin D 0 0 10 1
AN,  EAG Withaferin A 0 0 9 2
TME  Zerumbone 0 0 6 5
TIM  -(1-6)-D-glucan (A. blazei) 0 0 6 5
Totals: 7 18 403 221
Percentages: 1.08% 2.77% 62.10% 34.05%
a For each approach, the following items are shown: the hallmark(s) for which it was selected, and the number of other hallmarks with which it has complementary
relationships, contrary relationships, no known relationships and controversial relationships. For approaches that have contrary relationships, the conﬂicted hallmark(s) are
shown. Totals and percentages of each type of relationship are shown at the end of the table.
b AN, angiogenesis; AP, resistance to apoptosis; DM,  dysregulated metabolism; EAG, evasion of anti-growth signaling; GI, genomic instability; IE, immune evasion; RI,
r and m
a
p
o
d
aeplicative immortality; SPS, sustained proliferative signaling; TIM, tissue invasion 
c Targeted therapy, synthetic compound or natural product analog/derivative.
pproaches in order to comprehensively counter tumor growth
athways. So although we realized that not all of these reports
f cross-hallmark relationships represented the same level of evi-
ence, we still wanted to examine available evidence to ﬂag targets
nd approaches where procarcinogenic actions had been reported.etastasis; TME, tumor microenvironment; TPI, tumor promoting inﬂammation.
There was also considerable debate within the task force over
the value of tables containing only a simpliﬁed indication of a
relationship (i.e., + or −) supported by evidence that varied con-
siderably in quality. But since many individual studies and reviews
that focus on therapeutic approaches fail to work systematically
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across the spectrum of incidental actions that might result from
combining therapies, it was our opinion that a tabularized frame-
work was the only way to ensure that we had assembled a complete
view of cross-hallmark activity.
The types of approaches selected differed among different
review teams. While some review teams selected all or mostly phy-
tochemicals or plant extracts, some teams felt that the evidence for
these was  insufﬁcient, and emphasized other types of molecules,
including drugs in development. These may  pose more difﬁculties
for translational investigators due to intellectual property, toxic-
ity or other concerns, but may  offer advantages in a more clear
understanding of their mechanisms. We suggest, however, that the
approaches as well as the targets presented in Tables 1 and 2 can
be viewed as simply a model for broad-spectrum cancer therapies,
rather than as a ﬁnal list. Some of the recommended approaches
are clearly experimental, and further research will likely discover
compounds, phytochemical or synthetic, that are not on this list
that may  be useful in a broad-spectrum approach. The prevalence
of interactions where no interactions were found – over 20% for
targets and over 30% for approaches – also suggests caution and
a need for further research investigating potential cross-hallmark
relationships as well as other mechanisms that may  lead to toxi-
cities.
Bioavailability of the phytochemicals chosen will also be a
concern for future studies. The need for development of better
preclinical models for screening compounds and testing rationally
designed combinatorial therapies composed of compounds from
any source is also obvious, and should clearly be a ﬁrst step in the
development of the broad-spectrum approach.
4.1. Role of integrative therapies in the broad-spectrum approach
Integrative medicine is an approach to health and healing
that “makes use of all appropriate therapeutic and lifestyle
approaches, healthcare professionals and disciplines to achieve
optimal health and healing” [148]. A comprehensive integra-
tive medicine intervention for cancer patients typically includes
nutrition education, mind-body medicine and physical activity
components, as well as dietary supplements including herbs,
nutraceuticals and phytochemicals [3,149]. Such an interven-
tion may  contribute uniquely to a broad-spectrum therapeutic
approach through its impact on a wide variety of relevant molecular
targets and hallmarks. Hallmarks that may  be particularly impacted
include genomic instability, tumor-promoting inﬂammation, dys-
regulated metabolism and immune system evasion. Because of
their susceptibility to manipulation by diet, exercise and supple-
mentation, these may  be characterized as metabolic hallmarks.
Nutrition has long been the primary focus of research on inte-
grative interventions for cancer. The World Cancer Research Fund
and the American Institute for Cancer Research ﬁnd that diets high
in fruits and vegetables substantially reduce risks of several cancers
[150]. Cancer prevention diets are also suitable after a cancer diag-
nosis [151]. For example, colon cancer patients eating a Western
diet after diagnosis were at higher risk for recurrence and mortality
than those with healthy diets [152]. Breast cancer patients who fol-
lowed low-fat diets were found to have lost weight and had lower
recurrence risks, especially among patients with estrogen receptor-
negative cancers [153]. Trials of diets enriched in whole grains,
low-glycemic diets, and both low-fat diets and Mediterranean diets
enriched in olive oil and almonds reduced levels of inﬂamma-
tion as measured by CRP [154–157]. Low fat diets, weight loss
and supplements (anthocyanins and ﬁsh oil) have been observed
in randomized trials to reduce cytokines and signaling molecules
[158–161]. Mind-body interventions have emphasized immune
targets, with ﬁndings of interventional trials including activation of
T cells and lymphokine-activated killer cells and increased natural
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iller cell activity [162,163]. Exercise interventions have docu-
ented effects on survival, IGF-1, natural killer cell activity, and
ex hormones [164–167]. While much work remains to be done on
ntegrative interventions, preliminary data suggest that integrative
edicine may  signiﬁcantly support a broad-spectrum approach to
ancer therapy.
. Proposed research model
The review process for this project has revealed many potential
argets and approaches. The cross-validation activity suggests that
nly a small number of targets and approaches affect other hall-
arks in contrary or controversial ways. Indeed the results suggest
hat the design of a broad-spectrum approach should in fact be fea-
ible from a safety standpoint. Although considerable research will
e needed, disease relapse is a substantial and longstanding prob-
em, so this novel model deﬁnitely warrants further investigation.
.1. In vitro research
An array of in vitro models is available for preliminary study
f broad-spectrum formulas. One question is the suitability of
eceptor-based assays versus cell-based assays. While receptor-
ased assays may  seem more suitable for targeted therapy research,
xamining the impacts of a putative agent on a molecule such as
F-B, which is at the intersection of multiple signaling pathways
elated to inﬂammation, might be advised. Cultivated cell lines are
aluable for preliminary screening of mixtures, but are, in most
espects, limited in their predictive ability. Isolated cell lines from
linical samples are an alternative, and use of transformed cancer
ells versus non-transformed lines should be discussed. Tissue and
rgan explants are another useful in vitro model.
Basic research on the properties of the natural products and
ther approaches selected in the reviews needs to continue. The
harmacology of mixtures and combinations of phytochemicals,
ioavailability, dose optimization and synergy are among the areas
n which research is needed for many phytochemicals [168,169].
owever, multicomponent herbal therapies used in traditional and
lternative medicine have not received detailed analysis. Network
harmacology could be a means of exploring these presumed syn-
rgisms, and efforts are being made to apply this approach to
he complex herbal mixtures used in traditional Chinese medicine
170]. Studies on the pharmacokinetics of herbal extracts and phy-
ochemicals, which often begin at the in vitro level, are also needed
171].
In sum, given the complexity that is immediately suggested
hen combinations of approaches are possible, we strongly recom-
end that well-coordinated, multi-faceted programs be pursued
nitially to ensure that the constituent approaches that are selected
re well-characterized using in vitro models, and that delivery
ethods that are selected for in vivo work receive careful evalu-
tion before animal research is undertaken.
.2. In vivo research
Multiple in vivo models for further study of broad-spectrum
pproaches are also available. Two obvious choices are animal
umor models and human tumor xenografts implanted in athymic
ice. While human tumor xenografts have the advantage in pre-
icting effects of agents on human cancer cells, animal tumors
ffer some interesting choices for chemoprevention studies, since
everal are induced by exposure to various chemicals. The rodent
umors are questionable, however, in their ability to predict human
esponses to antitumor therapy. Differences in immunity are one
onsideration, most obviously with athymic mice but also with
ther animals. Many other differences are known. Rodents andBiology 35 (2015) S276–S304
humans, for instance, differ signiﬁcantly in their blood levels of
soy isoﬂavones after these are administered through a variety of
dietary and experimental routes [172]. Isoﬂavone levels in rodent
blood 20–150 times those in humans after similar oral intake have
been observed, raising questions about the suitability of animals
for prediction of phytochemical effects in humans.
Additionally, as shown in different preclinical mouse models,
immune and inﬂammatory responses to cancer differ in young
and old individuals, and many cancer treatments are likely to
be less effective at older ages. Combination treatment including
immunotherapeutic approaches may  be most suitable for older
animals. Therefore, there is a strong argument for testing and opti-
mizing combination treatments in suitable model systems before
attempting to apply them to cancer patients. The US National Can-
cer Institute Mouse Models of Human Cancer Consortium [173]
has tried to provide the scientiﬁc community with accurate, repro-
ducible models of human cancers that can be used in translational
and preclinical studies. Such improved models could be of great
importance for developing combination treatment strategies. Com-
panion animals, such as dogs and cats, which experience several
tumors analogous to human cancers, can also act as comparative
models for human tumors [174].
5.3. Clinical trials
Keeping in mind that a broad-spectrum approach may be used
not only by itself, but also as adjuvant therapy with conven-
tional agents, there are numerous potential settings for clinical
trials, either for proof of principle or therapeutic goals. Pre-
liminary studies could include metabolomic studies to identify
metabolites of dietary interventions, or the pharmacokinetics and
pharmacodynamics of phytochemical agents. A variety of settings
can be contemplated for clinical trials. One period during which
a broad-spectrum approach may  be particularly appropriate is
the perioperative period. Murine data demonstrate that tumor
growth accelerates after surgery; there are also numerous anec-
dotal reports regarding cancer patients in whom rapid growth of
metastatic tumors has been noted after surgery [175–180]. Further,
there is reasonable human evidence that colon or rectal resection
results in signiﬁcant increases in the plasma levels of numerous
proangiogenic proteins after surgery [181–184]. This period is not
generally used for chemotherapy administration because of fears
of impaired wound healing, but the above ﬁndings provide the
rationale and motivation for systemically administering selected
anticancer agents perioperatively.
Several non-standard chemotherapy agents, including phyto-
chemicals, have been administered perioperatively in small studies
[185–187]. These agents upregulate immune function via nonspe-
ciﬁc mechanisms. A Phase I trial assessing the combination of EGCG
and silibinin in colorectal cancer is underway, with both agents
given orally before and after surgery [188–190]. Such trials rep-
resent an innovative approach to clinical assessment of natural
products that can be carried out within a restricted time.
Although clinical trials of phytochemicals and plant extracts
in cancer are limited compared to those with conventional
chemotherapy, they are by no means lacking. Russo et al. [58]
review nearly 50 ongoing and completed trials of phytochemi-
cals and extracts in cancer prevention and therapy, noting that
even though clinical research is still limited, preliminary results are
promising. Most of the 50 studies took place in the United States,
and most included a single phytochemical or single-herb extract.
Nearly 3000 controlled trials of Chinese traditional medicine, 90%
concerning herbals, were reviewed by Li et al. [191]. Only 16%
of traditional medicine trials in this review reported use of ade-
quate methods of randomization, and only a very small percentage
reported study blinding, although quality of studies improved
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hrough time. Most Chinese herbal formulas contain multiple herbs
nd are aimed at many targets.
The design and execution of clinical trials of natural chemicals
rom plants and foods, however, has been challenging worldwide.
n herbal products extension of the Consolidated Standards of
eporting Trials (CONSORT) randomized trial reporting guideline
as been published to help improve herbal trial reporting [192].
 review of published studies of Panax ginseng, which is common
n Chinese formulas but has been studied globally for many con-
itions, found that only 48% of them reported CONSORT-suggested
tems, and only 39% reported items from the herbal products exten-
ion [193], although these study designs also improved over time.
.4. Translational considerations
Assuming that translational research work will involve a sub-
tantial combination of therapeutic agents such as those proposed
n Table 2 as a starting point, a ﬁrst step would be the selection of
peciﬁc targets and approaches for preliminary study. To achieve a
ruly broad-spectrum effect, one strategy might be to use small
oses of every approach that lacks signiﬁcant contrary interfer-
nces. While such a mixture might be made up and applied to
ell lines, it could be questioned whether the concentrations that
ould be achieved in the cells would be physiologically relevant,
specially given the low bioavailability of many phytochemicals.
ost in vitro work on single phytochemicals, however, has actually
een conducted at high concentrations that are not achievable in
umans. The pharmacokinetics and pharmacodynamics of phyto-
hemicals are complex and many are not yet well known, although
rogress is being made on some agents [194]. Another method
o narrow the number of phytochemicals that need to be in an
gent might be to select the phytochemicals that are most widely
epresented across hallmarks, such as curcumin and resveratrol,
nd analyze combinations of these agents. Some of the selected
pproaches, e.g. silibinin, appear to have favorable pharmacokine-
ics [195]. Other phytochemicals with favorable pharmacokinetics
ould also be considered for inclusion in a broad-spectrum agent,
uch as phenethyl isothiocyanate [196]. Research is also urgently
eeded on the question of the stability of phytochemicals as well
s synthetic compounds in mixtures.
Alternative approaches to the question of bioavailability are
eing explored, especially with the polyphenols. One of the main
ssues with these compounds, which include quercetin, green tea
atechins, curcumin and others, is ensuring that circulating doses of
glycones (one of the active forms of these molecules) are sufﬁcient
or activity. After oral supplementation of food-grade molecules at
oses safe for humans (200–500 mg/day), only conjugated forms
re found in the bloodstream. As an example, quercetin is not
ound in the plasma as aglycone or as the parent glycosides: at
he doses usually employed in intervention studies, it would be
ound exclusively as methyl, sulfate or glucuronic acid conjugates
197]. This observation discloses a paradox common to many bio-
ogically active phytochemicals: if free aglycones are absent in vivo
fter a dietary intake or supplementation with high doses, how can
e explain the high biological activity of these molecules, largely
escribed in vitro?
Two main hypotheses can be considered. First, conjugated forms
f some ﬂavonoids (e.g. quercetin) may  be biologically active. Sec-
nd, after cellular uptake, these metabolites may  be de-conjugated,
egenerating the free aglycones. To sustain these hypotheses, key
ssues need to be addressed, such as the efﬁcacy of mechanisms
f uptake of polyphenol metabolites and the substrate speciﬁcity
f each metabolite, which is largely unknown. The use of pure
ompounds tested in vitro may  shed light on these questions. Alter-
atively, pharmacological doses (2–4 g/day) administered orally
198] may  saturate the metabolic pathways of conjugation [199].Biology 35 (2015) S276–S304 S295
Efforts are being made, however, to improve bioavailability of these
agents, such as microspheres [200], liposomes [201] and nanopar-
ticles [202]. An additional complication is that individuals may
vary in their absorption, distribution, metabolism and elimination
of phytochemicals, based in some instances on genetic variability
[203], dietary habits [204] and potentially on intestinal microbiota
[205].
Considerations of quality control are essential along the spec-
trum of research from in vitro studies to clinical trials. Good
agricultural practice, correct botanical identiﬁcation and good
manufacturing practice are mandatory to prevent adulteration,
contamination and toxicity [206]. The example of PC-SPES, a
botanical cancer remedy that was  found to contain indomethacin,
warfarin and synthetic estrogens, leading to its withdrawal from
the market in 2002 resulted in greater awareness of the need for a
strict approach to quality control [207].
6. Implementation of broad-spectrum research agenda
A variety of practical considerations come into play in trans-
lating the proposed research model into a developmental program.
These include regulatory considerations, intellectual property, clin-
ical considerations and funding.
6.1. Regulatory considerations
Research on the broad-spectrum model must be undertaken
with regulatory constraints in mind. Laws controlling herbal
medicines, which would likely apply to the broad-spectrum
approach, typically have regulatory paths for herbal or traditional
medicine products that differ from those for prescription drugs.
Regulations relevant to traditional Chinese herbal medicines, per-
haps the closest model for the proposed broad-spectrum approach,
are reviewed by Fan et al. [208]. A few examples of national regula-
tions regarding herbal medicines, traditional medicines and natural
product drugs follow.
The United States has perhaps the most challenging regulations
for drug approval, and regulations for mixtures are particularly
complex. Some multicomponent formulas have nevertheless been
tested in clinical trials in the US [209,210], but are still being sold
only as dietary supplements, without labeling for use in malig-
nancy. The designation of the Botanical Drugs category may offer
opportunities to broad-spectrum agents. A recent court decision
declaring natural products unpatentable under US law adds an
interesting wrinkle to the regulatory framework [211]. In Canada,
development as a high-risk Natural Health Product could be con-
sidered [212]. China has a variety of regulatory categories that
could be used for multicomponent natural product therapeutics
[213]. The relevance of Chinese regulations for multi-targeted drugs
has been explored [214]. In the European Union, the Marketing
Authorization scheme for conventional drugs would need to be
used, rather than the Traditional Herbal Regulation Scheme [215],
increasing the challenge for developmental research. In India it is
likely that New Chemical Entity approval would be required [216],
since use in cancer would likely be considered beyond traditional
herbal medicine usage. Japan allows herbal medicines to be regis-
tered as prescription or over-the-counter drugs [208]; prescription
licensing appears likely for an anticancer therapeutic. A variety of
regulations exist in other countries, which are beyond the scope of
this paper, and which would need to be explored individually. We
expect that working under these strict regulations will be difﬁcult,
but we  do not see it as impossible.
An additional regulatory consideration is the acceptability of the
broad-spectrum approach to institutionally-based ethical review
boards needed for clinical research. In institutions located in
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ountries in which multi-component herbal formulas are typical
f traditional medicine, ethical approval of such formulas is com-
on, as suggested by the large numbers of clinical studies on
raditional Chinese herbal medicine [191] and Japanese Kampo
edicine [217]. Trials with multi-component formulas and natu-
al products have been conducted under other regulatory schemes
s well. For instance, Phase I and Phase Ib studies of BZL101, an
xtract of Scutellaria barbata in metastatic breast cancer have been
onducted in the United States [218,219]. A 4-herb combination
riginating in traditional Chinese medicine, PHY906, has been the
ubject of a Phase I trial as an adjunct to capecitabine in advanced
ancreatic cancer, also in the United States [220]. In general, pro-
ision of sufﬁcient preclinical and drug formulation information,
eview of prior clinical studies, and possession of appropriate
pprovals from national-level agencies will facilitate approval of
tudy protocols.
.2. Intellectual property
Herbs and natural products in their native forms do not have
ntellectual property protection, which should help in developing a
ow-cost, broad-spectrum formulation. Speciﬁed extracts and indi-
idual phytochemicals may  have intellectual property of various
ypes. Researchers could pursue intellectual property protection
or speciﬁc broad-spectrum therapeutics they develop, as well as
icensing to a pharmaceutical company with sufﬁcient resources
o support development and testing of the agent. Herbal extracts
f some complexity have received patent or trademark status,
nd have been granted drug approval even in the United States,
xamples include a mixture of green tea polyphenols known as
olyphenon E and sold as the patented drug sinecatechins for
enital warts [221], and crofelemer, an extract from the South
merican plant Croton lechleri,  approved for HIV-induced diar-
hea [222]. The complexities of natural product patenting are
eyond the scope of this paper but are covered in depth elsewhere
223].
.3. Clinical considerations for a multi-component natural
roduct therapeutic
Based on current clinical experience with natural products
dministered together with conventional drugs, one may  anticipate
otential concerns with broad-spectrum therapeutics that would
e administered jointly with conventional therapies. A primary
oncern is the interactions between drugs and herbs or phyto-
hemicals, including both pharmacokinetic and pharmacodynamic
nteractions [224]. This has been of special concern in oncology
ue to the life-threatening consequences of lowered blood levels
f drugs, and the potential for severe side effects when blood lev-
ls of a drug are increased or actions of herbal products reinforce
hose of conventional agents. Antiplatelet activity is common in
atural products [225], and may  aggravate clinical consequences
n patients with thrombocytopenia due to chemotherapy or other
rugs [226]. Several other examples of negative interactions are
nown or suspected. St John’s wort (used for depression) con-
ains the strong cytochrome P450 3A4 inducer hyperforin, which
s known to reduce blood levels of many drugs, including irinote-
an [227]. Green tea, which is often taken in high doses by
ancer patients, has potential interactions with sunitinib [228],
ith hepatotoxic drugs [229], and with bortezomib. On the other
and, positive interactions have been observed with green tea and
rlotinib, a combination now in clinical trials [230]. Curcumin is
ne of several natural products that act as chemosensitizers and
adiosensitizers for several tumors, while protecting normal tis-
ues [231]. The ability of herbs and other natural products to relieve
reatment-related side effects should not be overlooked [232,233].Biology 35 (2015) S276–S304
Furthermore, many natural products possess antioxidant activ-
ity. The role of oxidation in cancer progression and treatment is
controversial [234]. Oxidative stress is increased in late-stage dis-
ease [235], which suggests that suppression would be beneﬁcial.
Antioxidants may  relieve some adverse treatment effects caused
by the reactive oxygen species generated by many chemotherapy
drugs, but data on this point are not conclusive [236,237]. Random-
ized trials of antioxidant supplements given with chemotherapy
do not ﬁnd evidence of reduced efﬁcacy, but research with bet-
ter study design and larger sample size should be conducted [238].
Additionally, some natural antioxidants, including the polyphenols,
manifest pro-oxidant properties in cancer cells, due to interactions
with metal ions, which contribute to anticancer effects [239]. This
pro-oxidant effect has been hypothesized to underlie the broadly
multi-targeted actions of polyphenols such as curcumin and EGCG
[240]. However, activity of most chemotherapy drugs depends on
generation of ROS which should not be abrogated. Additionally,
some oxidative metabolites may  act as signaling molecules with
anticancer activity [241]. Further, intracellular antioxidants may
contribute to drug resistance [242]. Our understanding of the inter-
actions of antioxidants and cancer thus continues to develop [243].
Patients are often warned not to supplement with antioxidants
during treatment.
6.4. Funding
Development of new clinical agents that could be approved by
regulatory agencies is an expensive endeavor. A recent economic
model of drug discovery and development in the United States
used industry-appropriate assumptions to estimate that the fully
capitalized cost of a typical new single-molecule drug developed
is now approximately $1.8 billion, 63% of which is attributable
to clinical development (Phase I–III studies) [244]. The details
of such estimates are beyond the scope of this paper, but the
ﬁnancial challenges are clear. It is our contention that a multi-
component broad-spectrum therapeutic approach is needed to
complement and balance the current drug discovery paradigm,
which focuses on narrowly scoped approaches and singular molec-
ular targets, including targeted therapies, immunotherapy, “one
mouse-one patient” avatars that identify personalized therapeu-
tic regimens by implanting patients’ tumors into mice [245,246]
and a variety of other approaches. Such an approach could be
expensive to develop, and could face similar costs for trials
and approval. However, a broad-spectrum approach could be
aimed at wide applicability among many cancer types and sub-
types. Thus, initial investment could be more easily recovered
than is the case with narrowly-focused target therapies, since
it would have utility across a large group of patients. Whether
the development of the broad-spectrum approach should be
carried forward by governments, for-proﬁt pharmaceutical com-
panies or even non-proﬁt pharmaceutical companies is an open
question.
6.5. Importance for low- and middle-income countries
The possibility that a broad-spectrum approach could be devel-
oped that is both effective and inexpensive is an important
consideration, especially in low- and middle-income countries. One
of the cost components of drug development is the cost of target
identiﬁcation and validation. However, in the Halifax Project thefrom the open literature, so individual laboratories or nations
that are interested in developing a multi-component therapeutic
approach can use this information as a starting point (i.e., as a basis
for rationally selecting an array of targets).
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. Summary and conclusions
In spite of the importance of targeted therapies now used in
reatment and currently in development, it is clear that most
ancers cannot be successfully addressed solely with single-
arget therapies. The history of cancer treatment has taught us
he importance of drug resistance, stemming ultimately from
enetic heterogeneity in cancers. Our therapeutic tool kit now
ncludes a large array of cytotoxic chemotherapies, molecular tar-
et drugs, immunotherapies and hormonal therapies. A major
aradigm in cancer research, in response to the advances in anal-
sis of the cancer genome, is the development of increasingly
argeted therapies. Examples illustrating the vigor of research
nd development in this area are several targeted therapies that
ave received approval in 2013–2014 by the US FDA, including
eritinib (anaplastic lymphoma kinase inhibitor), ramucirumab
VEGFR2 blocker), ibrutinib (Bruton’s tyrosine kinase inhibitor),
rametinib (MEK inhibitor) and dabrafenib (B-Raf inhibitor)
244].
At the same time there is an increasing awareness of a need to
evelop a therapeutic approach to address the genetic heterogene-
ty within tumors. Even within this group of newly approved agents,
he combination of trametinib and dabrafenib was approved for
oint use in 2014, due to the rapid (6–7 months) development of
esistance to the sole use of B-Raf inhibitors. The emergence of the
oncept of multiple hallmarks of cancer [27], the nine pathways of
rogression [3] the listing of 138 driver genes [6] and the recog-
ition of the importance of network pharmacology [51] all attest
o the importance of this issue. A recent review similarly suggests
ombining antiinﬂammatory and antioxidant treatment in long-
erm maintenance therapy of cancer [247]. It is the contention of the
alifax Project that a broad-spectrum approach to cancer prophy-
axis and treatment (i.e., simultaneously attacking many targets) is
 strategic and promising response to our increasing understanding
f the signiﬁcance of genetic heterogeneity.
Although current drugs have notably increased initial respon-
iveness to treatment in comparison to traditional approaches to
hemotherapy, there remain situations in which a broad-spectrum
pproach could make real contributions. Some examples include
se as follow-up to conventional treatment; for rare cancers; for
atients who do not tolerate conventional treatment; for early-
tage disease, when aggressive treatment should be avoided; and
n hospice and palliative care. If signiﬁcant interactions with treat-
ents can be avoided, it might even be possible to use such
pproaches in conjunction with targeted therapies and other treat-
ents.
What are the implications of this broad-spectrum strategy
or current clinical practice? First, clinicians should realize that
his paper presents a developmental research program, not clin-
cal guidelines. Use of uninformed selections of phytochemical or
otanical extracts in poorly-deﬁned clinical situations is unlikely
o deliver positive results. Further, as noted above, concerns with
nteractions of natural products with conventional treatments
hould be kept in mind. That said, lifestyle therapies appear to
ffect multiple molecular targets and to improve the health of
ancer patients in a variety of ways, and integrative lifestyle mod-
ﬁcations should be assessed as a health-promoting foundation
or use of broad-spectrum therapeutics [3,149]. Clinical trials are
ow deﬁning beneﬁcial impacts of natural products [248]. The
ositive implications of dietary therapies for improvement of the
etabolic hallmarks of inﬂammation, dysregulated metabolism,
enomic instability and immune system evasion should be kept
n mind [249,250]. Clinicians choosing to use natural product sup-
lements should attend to product quality and be familiar with
dvances in the formulation of poorly absorbed polyphenols and
ther phytochemicals [200–202].Biology 35 (2015) S276–S304 S297
The development of the broad-spectrum approach is not with-
out cost. A primary need is further development of preclinical
models for testing of combinatorial therapies, including study of
the stability, pharmacodynamics and pharmacokinetics of agents
comprising multiple phytochemicals and other molecules. While
some of the targets and approaches recommended in these reviews
are well-known and have been the subject of multiple reviews,
others are still only promising leads and may  need much bet-
ter characterization before being adopted as constituents in such
an approach. For example, among approaches, curcumin, genis-
tein, resveratrol and EGCG boast a wealth of fundamental research,
whereas other approaches such as tripterine, oleanoic acid and
withaferin A will require additional basic research. Targets are also
in need of more basic research, especially in replicative immortality
and in dysregulated metabolism, a ﬁeld in which studies of rele-
vant targets are just beginning. The approaches analyzed in these
areas are similarly only in the most preliminary stages of research.
All the hallmarks, however, include targets and approaches that
need substantial basic research. Determining how many of the sug-
gested targets should be included in a broad-spectrum approach
is also a question that needs substantial research. Supporting
these areas of basic research should be an initial goal of funding
efforts.
The pharmacology of mixtures of natural products is another
area in which basic research is most relevant to the goals of this
project. There is certainly a body of research on complex mix-
tures of natural products [210,214,217,218,220]. A recent study
suggested that EGCG lowers the concentration of curcumin needed
to reduce proliferation and induce apoptosis in uterine leiomyosar-
coma cells [251]. Traditional Chinese medicine formulas have also
been subjected to extensive pharmacological testing [252,253].
However, much remains to be done in quantitative optimization
of formulas as well as in selection of optimal natural product
extracts or phytochemicals. And although this effort emphasized
phytochemicals, it is also important and relevant to study deﬁned
botanical and food extracts. Standardized black raspberry extract,
for instance, has produced positive results in human trials on
apoptosis, angiogenesis and several speciﬁc targets selected in
the project [254]. Aged garlic extract [255] increased immunity
in advanced cancer patients, and lyophilized strawberries [256]
improved premalignant esophageal lesions. Deﬁned herbal extracts
such as PHY 906 and BZL101 mentioned above have demon-
strated preliminary clinical antitumor activity [219,220]. Stability
and pharmacokinetic properties of complex mixtures are another
critical research need, as are proper methods of quality control
[257].
The development of complex natural product agents appears
ripe for cross-disciplinary approaches as well as attention to the
process of translational research. Natural products research, in fact,
has long been nurtured most successfully in multidisciplinary and
collaborative working groups [258], and the teams that authored
the reviews in this special issue were notably interdisciplinary
themselves. In view of the challenges as well as the unique oppor-
tunities this new concept entails, scientists wishing to take part in
the development of broad-spectrum approaches to cancer would
do well to commit themselves to a set of new attitudes and
skills. Laboratories and grant proposals have achieved success typ-
ically based on highly focused exploration of a small intellectual
niche. The broad-spectrum approach upends this paradigm. Build-
ing linkages with laboratories across campus, or even with the
department down the hall, is not always encouraged in academic
institutions. But this challenge is not insurmountable, and insti-
tutions and granting agencies have successfully mounted efforts
that embrace, for instance, natural product development “from the
ﬁeld to the clinic” [259,260]. At the same time, integrative oncol-
ogy centers globally employ broad-spectrum clinical approaches
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nvolving therapies ranging from natural products to meditation in
he service of patient needs [261]. There is thus no need to start
rom absolute zero in building the cross-disciplinary alliances we
roject will be needed for this effort.
What will be needed is a core group of scientists willing to
ecome advocates for this approach. Advocacy must take place
ithin academic institutions, as institutional silos, perhaps reluc-
antly, open their doors to collaboration. Institutional review
oards and grant ofﬁces may  need education in the concept of the
road-spectrum approach. Advocacy must take place at higher lev-
ls as well. National funding agencies and charitable foundations
hat currently support cancer research need to heed these rec-
mmendations and shift quickly to embrace the rationale for this
nterdisciplinary team-based approach. Grant review committees
ay  need to confront established interests promoting competing
tudies with more familiar narrow aims. Creativity in funding initial
esearch efforts will be needed. International agencies interested in
ddressing the growth of cancer in low to middle income countries
ight be convinced that broad-spectrum approaches could result
n lower-cost and often more culturally acceptable therapeutic
ools for these areas.
Now is the time to begin the work of advocating for broad-
pectrum therapeutic approaches in cancer. Scientists need to seize
he opportunities provided by the unique information provided in
his special issue to expand their acquaintance with this model
 and perhaps with the scientists themselves who are already
nvolved in this effort. Scientists and clinicians alike should become
dvocates to their institutions, to funding sources and to the wider
ublic. This dimension of cancer biology and therapy has too much
otential to allow it to languish. At the same time, clinical chal-
enges mount, despite the emergence of new targeted therapies. We
ook forward to seeing concentrated energy and intellect focused
n this new approach, and to seeing it yield signiﬁcant therapeutic
eneﬁts in the future.
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